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ABSTRACT
An Investigation of Bacterial Ribonucleases as an Antibiotic Target
by
Ashley Denise Frazier

Antibiotics have been commonly used in medical practice for over 40 years. However, the
misuse and overuse of current antibiotics is thought to be the primary cause for the increase in
antibiotic resistance.

Many current antibiotics target the bacterial ribosome. Antibiotics such as aminoglycosides and
macrolides specifically target the 30S or 50S subunits to inhibit bacterial growth. During the
assembly of the bacterial ribosome, ribosomal RNA of the 30S and 50S ribosomal subunits is
processed by bacterial ribonucleases (RNases). RNases are also involved in the degradation and
turnover of this RNA during times of stress, such as the presence of an antibiotic. This makes
ribonucleases a potential target for novel antibiotics.

It was shown that Escherichia coli mutants that were deficient for RNase III, RNase E, RNase R,
RNase G, or RNase PH had an increase in ribosomal subunit assembly defects. These mutant
bacterial cells also displayed an increased sensitivity to neomycin and paromomycin antibiotics.
My research has also shown that an inhibitor of RNases, vanadyl ribonucleoside complex,
potentiated the effects of an aminoglycoside and a macrolide antibiotic in wild type Escherichia
coli, methicillin sensitive Staphylococcus aureus, and methicillin resistant Staphylococcus
aureus.
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RNases are essential enzymes in both rRNA maturation and degradation. Based on this and
previous work, the inhibition of specific RNases leads to an increased sensitivity to antibiotics.
This work demonstrates that the inhibition of RNases might be a new target to combat antibiotic
resistance.
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CHAPTER 1
INTRODUCTION

Antibiotic Overview
Antibiotic resistance is a growing concern in the medical and research fields and is thought
to occur due to excessive use of current antibiotics in treating humans, animals, and agriculture.
In some cases, hospital-acquired bacterial infections have become almost untreatable due to
increasing antibiotic resistance. A summary diagram of antibiotic use for humans, animals, and
in the environment is seen in Figure 1.1 and depicts how the use of antibiotics in one group can
migrate to affect other groups (Davies and Davies 2010; Giedraitienė and others 2011; Rosen
2011; Tenover 2001). In addition to drug resistance among the pathogenic bacteria, there is also
a documented increase in antibiotic resistance of the normal flora. An example of this is
Escherichia coli, a gram negative bacterial species that is found in the normal flora of the human
bowels. This bacterial species has become a leading cause of urinary tract infections (Erb and
others 2007). Previous studies have demonstrated the increase in antibiotic resistance is not due
solely to hospital-acquired infections. Antibiotic resistant bacteria were originally thought to be
nosocomial, but these data indicates that community-acquired infections are becoming more
common, confirming that the spread of resistance is becoming more and more serious.
Before the 1940s, common treatments for bacterial infections were to insert a surgical drain
into the site of the infection and use antiseptics, but this was not an adequate treatment and many
bacterial infections were still fatal. A few years after antibiotics were first used to treat bacterial
infections, penicillin resistance began to occur. Since then, resistance has grown to encompass
various other antibiotics, including methicillin and vancomycin (Zinner 2005; 2007). By the
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1990s, methicillin resistant Staphylococcus aureus was no longer limited to hospital-acquired
infections, and community-acquired S. aureus began to appear more often (Hawkey and Jones
2009; Zinner 2007). Multiple bacteria species are now developing resistance to currently used
antibiotics, including Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, and
Mycobacterium tuberculosis (Giedraitienė and others 2011). In order to alleviate this growing
problem, researchers are attempting to identify new antibiotic targets and to create novel
antibiotics that contain unique structures to which resistance has not developed (Anderson 1999;
Cars and others 2011; Högberg and others 2010). Antibiotic resistance is thought to occur by
multiple different mechanisms. Some of these mechanisms include acquisition of resistance
genes, up-regulation of genes encoding cellular efflux pumps, and spontaneous mutations
(Zinner 2007). However, a better understanding of current antibiotic targets and how they
function in cells will allow for increased efficiency in antibiotic research.
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Figure 1.1: Overview of antibiotic use (Davies and Davies 2010). This figure indicates the use of
antibiotic in the ecosystem is not restricted to that group. The use of antibiotics in the
environment affects animals, humans, and the use of antibiotics in each of these groups also
affect the environment. (Used with permission)

Antibiotic Targets
Bacterial ribosomes are composed of a small 30S and a large 50S subunit (Champney 2006).
The 30S ribosomal subunit is composed of 16S ribosomal RNA (rRNA) and 21 proteins, while
the 50S ribosomal subunit is composed of 23S and 5S rRNA and 34 proteins. Both the large and
small subunits must be present to create the bacterial ribosome. Each subunit contains a specific
center essential to translation. The 30S subunit contains a decoding center, and the 50S subunit
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contains a peptidyl-transferase center. The decoding center is essential to the A binding site, and
the PTC center is essential to the P binding site (Wilson 2009). Research has shown that
antibiotics targeting these essential centers of the 30S and 50S subunits inhibit both subunit
assembly and bacterial protein synthesis (Champney 2006; McCoy and others 2011; Siibak and
others 2011). This indicates that inhibition of ribosomal subunit assembly and translational
inhibition might be a synergistic process (Champney 2006).
Many antibiotics act as translational inhibitors (Champney 2006; McCoy and others 2011;
Wilson 2009). During translation, mRNA brings a genetic code to the ribosome, and tRNA
carries the amino acids to the ribosome. For processing to continue, the mRNA and the tRNA
must move through the ribosome, i.e. progression must occur from the A site to the P site and
finally through the E site of the ribosome. The ribosome serves as a platform for the tRNA to
read the mRNA and create a nascent polypeptide chain. This is known as an elongation cycle
that must involve the decoding of the mRNA (at the small ribosomal subunit by tRNA), the
formation of a peptide bond, and release of the tRNA molecule at the peptidyl-transferase center
(PTC) of the large ribosomal subunit (Kaczanowska and Rydén-Aulin 2007). Decoding of the
mRNA by tRNA occurs within the A site. Next the tRNA carrying the nascent polypeptide chain
is moved to the P site for peptide bond formation. Finally, the tRNA that is ready to exit the
ribosome is moved to the E site. This tRNA is ready to exit the ribosome because it has
transferred the amino acid to the nascent chain and is now uncharged (Wilson 2009). Once the
mRNA has been completely read, the recycling of ribosomal subunits of the 70S ribosome is the
final step in the protein synthesis cycle and must be completed in order to repeat the cycle
(Borovinskaya and others 2007; Kaczanowska and Rydén-Aulin 2007; McCoy and others 2011;
Poehlsgaard and Douthwaite 2005; Ramakrishnan 2002; Yonath 2005). A diagram of the
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mechanism of translation is seen in Figure 1.2 (Ramakrishnan 2002). Many antibiotics act by
targeting the decoding and PTC centers to inhibit protein synthesis in a bacterial cell (Wilson
2009). In addition to translation, another target of many antibiotics is the formation of the
bacterial ribosome (Champney 2001; 2006; Wallis and Schroeder 1997).

Figure 1.2: A diagram of translation (Ramakrishnan 2002). The following figure indicates the
progression of tRNA through the A, P, and E sites of the bacterial ribosome as it reads mRNA.
(Used with permission)

When assembly of either of the ribosomal subunits is inhibited, ribonucleases (RNases) have
been found to degrade the ribosomal subunit assembly intermediates as seen in Figure 1.6
(Champney 2006). RNases are involved in rRNA processing to generate the 30S and 50S
ribosomal subunit and RNA degradation. When an inhibitor, such as an antibiotic, is introduced
specific RNases function in the recycling of the ribosomal precursors via rRNA turnover. This
makes bacterial ribosome formation and RNases two important targets for the development of
novel antibiotics to help fight antibiotic resistance. In order to understand antibiotic resistance, it
is important to first have a basic knowledge of antibiotic functions.
Two families of antibiotics that specifically target both translation and ribosomal subunit
assembly are the aminoglycoside and macrolide antibiotics. Aminoglycosides specifically target
the bacterial ribosome and not eukaryotic ribosomes due to differences in amino acids at the
target site on the ribosome and in cell membrane permeability (McCoy and others 2011).
17

Neomycin and paromomycin are two aminoglycosides that have been demonstrated to inhibit
30S ribosomal subunit assembly in wild type E. coli (Foster and Champney 2008; Mehta and
Champney 2002) and in S. aureus (Mehta and Champney 2003). Aminoglycosides have also
been shown to bind to the 50S ribosomal subunit (Borovinskaya and others 2007; Campuzano
and others 1979; Scheunemann and others 2010). The aminoglycoside antibiotics have a positive
charge that allows for the strong attraction to the negatively charged RNA (Shakil and others
2008). These antibiotics work by targeting both 30S and 50S ribosomal subunit assembly.
Treatment with neomycin (Figure 1.3), a member of the aminoglycoside family, has been found
to degrade the bacterial ribosome subunits by 60% in glucose starved cells (Zundel and others
2009). One interpretation of the decrease is that ribosomal subunits that are not assembled into
active ribosomes are subject to degradation by bacterial ribonuclease.

Ring I

Ring II

Ring IV
Ring III

Figure 1.3: Structure of neomycin
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Research indicates that the two main binding sites for aminoglycosides are 16S rRNA helix
44 and 23S rRNA helix 69 (Feldman and others 2010; Scheunemann and others 2010). The
binding reduces, or in some cases completely inhibits, the ability of the ribosome recycling factor
to recycle ribosomes by blocking this area of 23S rRNA. Helix 69 is also responsible for forming
a bridge with the smaller 30S ribosomal subunit and the A and P sites of the ribosome. When the
A site is blocked, the transfer from the A site to P site malfunctions and mistranslation occurs
(Borovinskaya and others 2007; Hirokawa and others 2005; Scheunemann and others 2010;
Schroeder and others 2000; Yonath 2005).
When binding to the 30S subunit, aminoglycosides bind to helix 44 of 16S rRNA. This
binding displaces two adenine residues and leads to a stabilized confirmation of one or more of
the four inter-subunit bridges. These two adenine residues are located in the A site of the
ribosome and when displaced, the mRNA and tRNA binding specificities to this site are
decreased leading to mistranslation and eventual cell death (Sutcliffe 2005). Paromomycin
(Figure 1.4) is thought to function by binding to the 16S rRNA. In this antibiotic, ring IV makes
contact with both sides of the helix 44 while ring I inserts itself into the RNA helix and is
directly responsible for the displacement of adenine 1492 and adenine 1493 (Carter and others
2000). This displacement inhibits the movement of the 70S ribosome, thereby inhibiting the
translocation of transfer RNA to a new position on the ribosome. The increased stabilization also
prevents dissociation of the 30 and 50S ribosomal subunits and subsequent ribosome recycling
(Carter and others 2000; Długosz and Trylska 2009; Sutcliffe 2005; Tenson and Mankin 2006).
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Ring I

Ring II

Ring III

Ring IV

Figure 1.4: Structure of paromomycin

Macrolide antibiotics are a family of antibiotics that have a 12-16 membered macrolactone
ring and include the antibiotics erythromycin and azithromycin (Figure 1.5). Macrolides have not
been shown to affect 30S subunit formation even at high antibiotic concentrations (Silvers and
Champney 2005). These antibiotics function by binding to the upper portion of the peptide exit
tunnel, below the peptidyl-transferase center of the 50S ribosome. The binding occurs at
nucleotides A2058 and A2059 via hydrogen bonds. This binding places the lactone ring of
macrolides against the exit tunnel and blocks it so that the newly made peptide chain cannot
elongate. The growth of the peptide chain is hindered depending on the bulk of the macrolide
antibiotic, so that the bulkier antibiotics will result in a shorter peptide chain
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(Bogdanov and others 2010; Kannan and Mankin 2011; Sutcliffe 2005; Tenson and Mankin
2006). Macrolides, such as azithromycin, are derivatives of the original macrolide, erythromycin,
and are more flexible due to having a 15 membered macrolactone ring rather than the original 14
membered ring. The altered ring also has an increased size and leads to the antibiotic occupying
more space in the exit tunnel. With more space being occupied in the exit tunnel, the antibiotic
efficiency for inhibiting the elongation of the protein in increased (Yonath 2005). When binding
to the ribosome, only one molecule of azithromycin can bind to a single ribosome (Petropoulos
and others 2009). In addition to blocking polypeptide elongation, macrolide antibiotics can also
bind to an intermediate of the 50S subunit, the 32S precursor. When wild type S. aureus cells or
RNase E deficient E. coli cells were incubated with erythromycin, there was an accumulation of
23S rRNA and 32S precursor. These data are indicative of stalling of the assembly of the 50S
ribosomal subunit (Pokkunuri and Champney 2007; Usary and Champney 2001). It has also been
determined that macrolide selectivity for bacteria is based on the adenine at position 2058 of 23S
rRNA. This adenine is conserved in bacteria but in eukaryotes it is a guanine residue (Mankin
2008; McCoy and others 2011; Starosta and others 2010).

21

Figure 1.5: Structure of azithromycin

These data, taken together, describe the mechanisms of action for two classes of antibiotics.
By better understanding the mechanisms of actions of current antibiotics, new targets for novel
antibiotics can be explored to fight against antibiotic resistance.
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Figure 1.6: Diagram of bacterial ribosome assembly. This diagram shows that RNases are
involved in ribosomal precursor processing and rRNA turnover (Champney 2006)

Bacterial Ribonucleases
Extensive research has been conducted to determine the functions of various ribonucleases
in rRNA maturation, rRNA degradation, and ribosomal subunit assembly. In the bacterial cell,
there are three main categories of RNA: messenger RNA (mRNA), transfer RNA (tRNA), and
ribosomal RNA (rRNA). Between these categories, rRNA is the most abundant, and mRNA has
the largest turnover rate (Li and others 2002). RNases play key roles in the degradation and
maturation of each of these types of RNA. For example, RNase PH has been found to be
involved in the processing and degradation of tRNA (Kelly and others 1992; Li and Deutscher
1994). mRNA degradation begins with the endonucleolytic cleavage by RNase E. RNase II then
functions in degradation of the poly(A) tail and subsequent degradation of mRNA
23

(Mohanty and Kushner 2000). Once bound to the ribosome for translation, a region of 15
nucleotides in mRNA is protected from degradation by RNases (Rauhut and Klug 1999). These
are just a few of the functions of RNases involving mRNA and tRNA. RNases also have
significant roles in maturation and in degradation of the most abundant RNA in a bacterial cell,
ribosomal RNA.
During assembly of the 30S and 50S ribosomal subunits, ribonucleases have been shown to
play a key role in rRNA turnover when an inhibitor is present (Champney 2006). It was
previously concluded by Silvers and Champney that E. coli strains deficient for certain RNases
were enhanced in their sensitivity to the macrolide, azithromycin (Silvers and Champney 2005).
Strains deficient in RNase E or polynucleotide phosphorylase (PNPase) were hypersensitive to
azithromycin. In addition to an increased sensitivity to azithromycin, E. coli with these RNase
deficiencies showed an accumulation of 23S rRNA and a reduced recovery rate of subunit
formation after the removal of the antibiotic. It was ascertained that azithromycin decreased the
assembly of the 50S ribosomal subunit and increased the accumulation of the 32S precursor to
the 50S ribosomal subunit (Silvers and Champney 2005). Figure 1.6 depicts the pathway for 50S
synthesis (Champney 2006). After azithromycin removal, the recovery rate of the 50S ribosomal
subunit was slowest in RNase E deficient, PNPase deficient, or RNase II deficient E. coli strains.
These data suggest that RNase E, RNase II, and PNPase play an important role in 23S rRNA
turnover and identify a possible mechanism for antibiotic resistance (Silvers and Champney
2005). It is possible that an increase in RNases leads to a decrease in antibiotic sensitivity and an
inhibition of specific RNases will lead to an increase in antibiotic sensitivity. A summary of
these data can be seen in Table 1.1.
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Table 1.1: Effect on ribosome deficiency on azithromycin sensitivity and 50S subunit assembly
in E. coli. Adapted from Silvers and Champney (Silvers and Champney 2005)
RNase

Type

I
Endo
II
Exo
III
Endo
E
Endo
PNPase Exo

Function
Synthesis Degradation

+
+

+
+
+
+
+

Azithromycin
Sensitivity

Inhibit 50S Assembly

Effect
Increased rRNA Fragmentation

+

+

+

+
+

+
+

+
+

Silvers and Champney’s work illustrates the importance of RNases in the turnover of 23S
rRNA in the presence of a macrolide antibiotic (Silvers and Champney 2005). A better
understanding of the function of some of the currently recognized RNases can provide a more
focused use for antibiotics. A list of some of the known ribonucleases is shown in Table 1.2.
Based on the functions of RNases and previous work showing that E. coli deficient for specific
RNases displayed a reduction in ribosomal subunit formation (Silvers and Champney 2005;
Usary and Champney 2001), it is possible that RNases could be used as a novel antibiotic target.
Compounds which subsequently block RNases that function in ribosome assembly or
degradation would be predicted to affect the sensitivity of current antibiotics.
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Table 1.2: Summary of ribonuclease functions

RNase Type of Ribonuclease
I
Endo
II
Exo
III
Endo
E
Endo
G
Endo
R
Exo
PNPase
Exo
PH
Exo

Function
Maturation Degradation
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes

RNase I
RNase I is an endoribonuclease located in the periplasmic region of the bacterial cell. It
functions in cleavage of RNA and is used as a defense mechanism against invasion by
bacteriophage (Arraiano and others 2010; Raziuddin and others 1979). Degradation of RNA can
occur by this enzyme due to cell damage. When the cell is damaged, it is hypothesized that
RNase I is able to leave the periplasmic region, enter into the cell, and degrade ribosomal RNA.
It is theorized that RNase I functions to forage nucleotides from the extracellular environment
(Arraiano and others 2010). However, the enzyme is normally kept inactive by unknown
mechanisms (Deutscher 2006; 2009).

RNase III
RNase III is an endoribonuclease encoded by the rnc gene and is responsible for cleavage of
the primary rRNA transcript (Allas and others 2003; MacRae and Doudna 2007). This cleavage
separates rRNA precursors into 17S, 25S, and 9S precursors, as seen in Figure 1.7, and initiates
ribosomal subunit RNA processing (Kaczanowska and Rydén-Aulin 2007). Figure 1.7 is a
diagram of how various RNases process ribosomal RNA (Davies and others 2010). RNase III is
26

involved in the cleavage of dsRNA (Xiao and others 2009). 16S and 23S rRNA sequences form
double-stranded regions at the 3’ and 5’ ends that must be removed in order to further process
the rRNA into the mature forms. King et al. determined that in an RNase III deficient E. coli
strain, the 16S rRNA had a mature 5’ end and 3’ end while the 23S rRNA did not have a mature
5’ or 3’ end (King and others 1984). These results further demonstrated that RNase III was
mechanistically the first RNase to cleave the primary RNA transcript (King and others 1984).
Further research has found that in α-proteobacteria, RNase III cleaves 23S rRNA at helix 9 of the
3’ terminus. This cleavage is important to the maturation of the 3’ terminus (EvguenievaHackenberg and Klug 2000).
Final maturation of both 23S and 16S occurs via additional ribonucleases. Without RNase
III and the initial cleavage, rRNA maturation will not occur. RNase III has been shown to
interact with the 70S ribosome and the ribosomal subunits (Allas and others 2003). This
interaction is thought to play a role in rRNA precursor maturation. RNase III cleaves the 23S
rRNA precursor 3 nucleotides downstream of the mature 5’ terminus in the ribosome. RNase III
has also been implicated in final maturation of ribosomal RNA, which occurs when RNase III
binds to the 70S ribosome to facilitate final 23S rRNA maturation within the ribosome (Allas
and others 2003).
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Figure 1.7: A diagram indicating significant functions of some RNase in RNA maturation.
Modified from Davies et al. 2010 (Davies and others 2010). The diagram shows that RNase III is
responsible for the initial cleavage of the rRNA transcript. In order to produce functional 16S,
23S, and 5S rRNA, additional RNases are necessary for maturation. (Used with permission)

RNase E
RNase E is an endoribonuclease, encoded by the rne gene, that forms part of the
degradosome particle with the enzyme polynucleotide phosphorylase (PNPase), an
exoribonuclease involved in RNA decay (Arraiano and others 2010). These two ribonucleases,
along with enolase and the DEAD-box helicase RhlB interact to form the degradosome (Vanzo
and others 1998). This complex is responsible for degradation of rRNA in addition to mRNA.
RNase E is an important enzyme in this complex because the other three components of the
degradosome each bind to the carboxyl-terminal end of RNase E. This further demonstrates the
significance of RNase E in RNA degradation. Along with the ribonucleases, RhlB is responsible
for unwinding the RNA to allow for degradation. Enolase has an undefined function within the
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degradosome (Vanzo and others 1998; Worrall and Luisi 2007). Studies have revealed that
mutations eliminating the C-terminus of RNase E result in a disruption of the degradosome
particle. However, the loss of the C-terminus also led to a reduction in cell growth, an increase in
stabilized mRNA, and 5S rRNA maturation remained unaffected. This suggested that the Cterminus of RNase E is involved in degradation and not rRNA processing (Lopez and others
1999). Once assembled, the degradosome functions in degradation of 16S, 23S, and 5S rRNA.
Evidence has shown that the cleavage associated with the degradosome is due to RNase E
cleavage and not the ribonucleolytic cleavage activity of PNPase (Bessarab and others 1998). E.
coli cells deficient for RNase E have been found to be hypersensitive to erythromycin. These
cells also have a 70% reduction in the 50S ribosomal subunit and an increase in 50S precursor in
the presence of the antibiotic. These data indicate that RNase E plays an important role in
degradation of antibiotic impaired ribosomal subunits (Usary and Champney 2001).
Studies have shown that in addition to degradation, RNase E is involved in maturation of
rRNA (Figure 1.7). RNase E, along with RNase G, has been implemented in the cleavage of E.
coli 16S rRNA. The enzyme removed 115 nucleotides from the 5’ terminus of the rRNA
precursor to produce a mature 16S rRNA 5’ end (Li and others 1999; Wachi and others 1999).
RNase E is involved in the maturation of 5S rRNA by cleaving both the 3’ and 5’ termini
(Arraiano and others 2010; Gutgsell and Jain 2012). In α-proteobacteria, RNase E has been
implicated in the processing of 23S rRNA at the 5’ end. This processing occurs at helix 9
following the initial cleavage by RNase III (Klein and Evguenieva-Hackenberg 2002). It stands
to reason that RNase E might be involved in 23S rRNA processing in other gram negative
bacteria similar to that of α-proteobacteria. However, no evidence has been published to-date.
Taken together, the data demonstrate that during rRNA maturation, RNase E is an essential
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ribonuclease that processes 16S and 5S rRNA. Some research also indicates an involvement in
23S rRNA maturation, depending on the bacteria. Furthermore, research has revealed an
importance of RNase E in rRNA degradation (Bessarab and others 1998).

RNase G
RNase G is an endoribonuclease homolog of RNase E and has been shown to act similarly
to RNase E (Tock and others 2000). Like RNase E, RNase G is involved in the maturation of the
5’ end of 16S rRNA. Strains deficient for RNase G lack a mature 5’ end of 16S rRNA but retain
a mature 3’ end. Without the mature 5’ end of 16S rRNA, translational function is decreased (Li
and others 1999; Roy-Chaudhuri and others 2010). In strains that are deficient for RNase G,
there is an accumulation of a 16S rRNA precursor. These data further indicate that without
RNase G, 16S rRNA cannot be processed correctly. While RNase E and RNase G are similar
ribonucleases, they have different recognition sites on the rRNA as indicated in Figure 1.7
(Wachi and others 1999). Studies have shown that the cleavage of the 5’ terminus of the rRNA is
accelerated by a monophosphate residue that serves to stimulate RNase G (Jiang and Belasco
2004). RNase G is also involved in the processing of 23S rRNA, where it functions by
processing the 5’ end of the ribosomal RNA (Song and others 2011). Taken together, these
studies show that RNase G functions to process 16S and 23S rRNA at the 5’ end but, unlike
RNase E, has not been shown to function in RNA degradation.
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RNase R
RNase R is a 3’-5’ exoribonuclease encoded by the rnr gene. RNase R is responsible for the
degradation of 16S and 23S rRNA; however, it does not degrade 5S rRNA very well (Cheng and
Deutscher 2002). This enzyme has been shown to increase during conditions of stress and is
involved in pathogenesis by various microorganisms (Chen and Deutscher 2010; Matos and
others 2009). When E. coli cells lack both PNPase and RNase R, the cells are no longer viable.
Due to the fact that cells deficient for RNases R and PNPase are not viable, it is possible that
these two ribonucleases are a common function that is essential for cell survival. This common
function might be the degradation and turnover of rRNA. Cells lacking PNPase and RNase R
showed an increase in 16S and 23S rRNA fragmentation. It has been suggested that this
accumulation of RNA fragments is lethal to the bacterial cell (Cheng and Deutscher 2003).
RNase R degrades RNA fragments by binding to a 3’ terminal overhang of at least seven
nucleotides (Vincent and Deutscher 2006). It is the only ribonuclease that has been found to
degrade double stranded RNA without the help of a helicase, provided that the 3’ end overhang
is single-stranded. Research has also demonstrated that RNA must thread through the RNase R
protein before degradation can occur, indicating that the enzyme does not merely attach to RNA
to begin degradation. RNase R does not degrade RNA via the 5’ end. It has been determined that
the RNB domain or C-terminal of the enzyme is essential for RNA degradation. This domain is
crucial because of Asp280, which must be present for degradation to occur. This amino acid
contributes to the ribonuclease’s ability to degrade RNA but not to the binding of RNA (Matos
and others 2009; Vincent and Deutscher 2006).
As previously stated, many RNases are regulated by the presence or absence of other
RNases. The cleavage of the rnr gene is regulated by RNase E. When RNase E is absent or
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down-regulated in cells, the rnr operon stability is increased and RNase R protein is increased.
This increased stability and protein production is possibly due to the lack of the degradosome
(Cairrão and Arraiano 2006). These data further demonstrate the close connection and regulation
of various bacterial ribonucleases. In addition to its regulation by RNase E, RNase R bears a
resemblance to RNase II. The two enzymes share a 60% homology with each other. PNPase,
RNase R and RNase II are the three major exoribonucleases in a bacterial cell (Awano and others
2010; Matos and others 2011).
RNase R is up-regulated in a cell during stress, such as starvation or dramatic temperature
changes. Under conditions of stress, the enzyme is stabilized; however, during the normal
exponential phase of cellular growth RNase R is very unstable. This raises the possibility that the
cell increases RNase R during times of stress to degrade damaged ribosomal RNA but is not used
as much for quality control purposes (Chen and Deutscher 2005; 2010). This RNase R-mediated
degradation of rRNA during stress may be important since an accumulation of fragmented RNA
can be toxic to the bacterial cell.

RNase II
Like RNase R, RNase II is a 3’-5’ exoribonuclease. It is encoded by the rnb gene (Matos
and others 2011). RNase II is thought to be involved in the removal of the poly (A) tail to protect
mRNA from degradation and its presence has been shown to be regulated by PNPase. RNase III
and RNase E indirectly affect RNase II by modulating PNPase and degrading RNase II mRNA
respectively (Arraiano and others 2010; Zilhão and others 1995). RNase II is able to bind both
DNA and RNA but distinguishes between the two based on the Tyr313 and Glu390 of the enzyme.
Tyr313 of RNase II is responsible for the recognition of RNA, and Glu390 of RNase II is
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responsible for recognition of DNA. For RNA degradation to occur, Asp209 of the enzyme must
be present. This exoribonuclease has been shown to become a “super enzyme” when a sitedirected mutation occurs that converts Glu542 to Ala542. Once converted to a super enzyme,
exoribonucleolytic cleavage is increased approximately 100-fold and RNA binding is increased
by about 20-fold (Arraiano and others 2010; Matos and others 2011; Zuo and Deutscher 2001).
Under normal circumstances, RNase II is involved in both rRNA maturation and
degradation. It has been documented that when RNase II is absent from E. coli cells, there is an
accumulation of the 30S and 50S ribosomal precursors (Corte and others 1971). The data also
showed an increase in the 16S rRNA precursor, 17S rRNA, when RNase II was inactive. These
results indicated a role of RNase II in ribosomal precursor maturation and in the maturation of
17S to 16S rRNA (Corte and others 1971). Studies have shown that E. coli cells deficient for
RNase II display a large reduction in the formation of the 50S subunit and an increase in 23S
rRNA fragmentation (Silvers and Champney 2005). Taken together, these data indicate a role in
maturation of 16S rRNA and the degradation and turnover of 23S rRNA.
Silvers and Champney found that E. coli cells deficient for RNase II demonstrated a
decrease in the 50S ribosomal subunit amounts and an increase in 23S rRNA when the macrolide
antibiotic, azithromycin, was present. Further research revealed that when azithromycin was
removed, there was a significantly reduced rate of recovery in these cells. These data indicated
that RNase II is important to the degradation and turnover of antibiotic-stalled ribosomes (Silvers
and Champney 2005).
RNase II and RNase R are homologs of each other and share approximately 60%
similarities. These enzymes do, however, have a few key differences. One difference between
these two members of the RNase II super family is the type of final end product that is released.
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For its final product, RNase II releases a fragment of four nucleotides in length. RNase R
releases a two nucleotide fragment. This difference is due to the aromatic amino acid locations in
the RNase. For RNase II, Tyr253 and Phe358 lock onto the RNA. Tyr253 is responsible for
determining the end fragment size. For RNase R, Tyr324 and Phe429 lock onto the RNA and Tyr324
is responsible for the end fragment size. While Tyr324 is responsible for determining fragment
size, studies have shown that the position of the phenylalanine determines how tightly the
enzyme fastens onto the RNA. The final end product is an important distinction because studies
have shown that the four nucleotide product must be further degraded to a two nucleotide
product in order to be recycled (Matos and others 2009; Matos and others 2011). Another
important difference between the two enzymes is the C-terminal tail. RNase R does not need the
assistance of a helicase in order to degrade RNA while RNase II does. This is due to the presence
of a lysine-rich C-terminal tail in RNase R that is not found in RNase II (Matos and others 2011).
These differences are important distinctions between two degradative ribonucleases and further
exemplify their functions.

PNPase
Polynucleotide phosphorylase (PNPase) is a 3’-5’ exoribonuclease and, along with RNase
PH, is a member of the PDX family (Arraiano and others 2010). PNPase is encoded by the pnp
gene and functions solely in RNA degradation. This enzyme is part of a larger complex in
bacterial cells, known as the degradosome (Mohanty and Kushner 2003). When a bacterial cell is
deficient for RNase II or RNase III, PNPase levels are increased. PNPase functions to regulate
RNase II by degrading the RNase II mRNA (Arraiano and others 2010). Studies have found that
RNase E has a direct interaction with PNPase, enolase, and RhlB. While PNPase appears to bind
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with RhlB, there does not appear to be any direct binding of PNPase with enolase and the
interaction must occur through RNase E (Burger and others 2011).
PNPase and RNase PH are the only RNases that require a phosphate group at the end of the
RNA group in order to break the phosphodiester bond and cleave the RNA (Zhou and Deutscher
1997). In order to begin the process of degradation, a single stranded RNA must have an RNA
overhang that ranges from 7-10 nucleotides in length at the 3’ end (Arraiano and others 2010). E.
coli cells deficient for PNPase have been shown to have an accumulation of 23S rRNA in the
presence of azithromycin and a reduced recovery rate when the antibiotic was removed. This
information indicates an importance of PNPase in rRNA degradation when an antibiotic is
present (Silvers and Champney 2005).
In E. coli cells deficient for RNase R and temperature sensitive for PNPase, there is a large
accumulation of 16S and 23S rRNA, suggesting that these two enzymes play a key role in the
degradation and turnover of this RNA (Zhou and Deutscher 1997). E. coli cells deficient for both
PNPase and RNase PH grow much slower than wild type E. coli cells. These cells also show a
decrease in the 50S ribosomal subunit and an increase in RNA degradation products
sedimentating in sucrose gradients between 4S and 16S. These results suggest that the subunit is
unable to assemble correctly which leaves the rRNA susceptible to degradation (Zhou and
Deutscher 1997).

RNase PH
RNase PH is a 3’-5’ exoribonuclease belonging to the PDX family (Arraiano and others
2010; Worrall and Luisi 2007). This enzyme binds to the last 4 nucleotides of single stranded
RNA to begin degradation (Lorentzen and Conti 2005). RNase PH has been shown to be
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involved in tRNA maturation; however studies are revealing an increasingly important role of
the enzyme in rRNA degradation and maturation. RNase PH has been implicated in rRNA
degradation during starvation, and it has been shown that the degradation of 16S rRNA at the 3’
terminus is facilitated by RNase PH (Basturea and others 2011). Studies have found that the
deletion of RNase II and RNase PH or the deletion of RNase PH and PNPase results in a large
increase in the 23S rRNA precursor. Analysis of the RNA in these cells revealed unprocessed
nucleotides of the 23S rRNA that are approximately 5-6 nucleotides in length (Gutgsell and Jain
2012). RNase PH was concluded to be the ribonuclease preferred to cleave 23S rRNA due to the
following factors. First is that in the precursor form, 23S rRNA 3’ end has a short overhang of
approximately three nucleotides followed by base pairing with the 5’ end. RNase II and PNPase
are not as effective as RNase PH at cleaving this region. Second, the presence of two cytosines at
the 3’ end of 23S rRNA, which inhibit final rRNA maturation by RNase T. Together, these data
show that RNase PH can initiate maturation by cleavage of the duplex region and removal of the
CC sequence. This then allows RNase T to cleave and mature the 3’ end of 23S rRNA (Gutgsell
and Jain 2012). These data point to RNase II and PNPase playing a role in 23S rRNA
degradation and also indicate that RNase PH plays a pivotal role in this process.
In summary, the eight RNases shown in Table 1.2 have been found to function in rRNA
maturation and degradation. Various studies have indicated increasingly important roles of
RNases when antibiotics are present (Silvers and Champney 2005; Usary and Champney 2001).
However, ribonuclease deficient mutants are not naturally occurring. Treatment with an RNase
inhibitor might act to mimic the results seen with various RNase deficient mutant bacteria, and
potentially provide a novel mechanism for increasing the effectiveness of antibiotics which act
by blocking ribosome assembly.
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Vanadyl Ribonucleoside Complex
Vanadyl ribonucleoside complex (VRC) is a RNase inhibitor. This complex is commonly
used to reduce RNA degradation during the isolation of RNA (Berger 1987; Berger and others
1980). While it is unknown which RNases are inhibited, it is theorized that VRC functions to
inhibit endoribonucleases (Berger 1987). Lee et al. found that 10mM VRC inhibited recombinant
RNase H activity by 90% (Lee and others 1997). To-date, there has been no published research
indicating the use of RNase inhibitors to inhibit ribonuclease function in a cellular system.
Previous data has shown that E. coli cells deficient for RNases are more susceptible to antibiotics
(Silvers and Champney 2005; Usary and Champney 2001). It is possible that the use of an RNase
inhibitor to inhibit bacterial RNases in the cell would serve as a novel antibiotic therapy.
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Research Hypothesis
Many current antibiotics operate by inhibiting the assembly of the bacterial ribosome
(Champney 2003; Champney and Burdine 1998a; Champney and Miller 2002; Champney and
Rodgers 2007; Champney and Tober 2000; Chittum and Champney 1995; Mehta and Champney
2002; 2003). It is known that ribonucleases play an important role in bacterial ribosomal subunit
assembly (Awano and others 2010; Gutgsell and Jain 2012; King and others 1984; Klein and
Evguenieva-Hackenberg 2002; Li and others 1999; Song and others 2011; Xiao and others
2009). RNases also play a key role in rRNA degradation. When an inhibitor such as an antibiotic
is introduced to the bacterial cell, under normal circumstances, RNases function to degrade the
ribosomal precursors and to allow the rRNA nucleotides to be recycled and reused (Figure 1.6).
Previous research has shown that when E. coli cells are deficient for RNases II, E, or PNPase,
these cells display a hypersensitivity to azithromycin (Silvers and Champney 2005).
It is hypothesized that the loss of RNases will increase the sensitivity of E. coli to
aminoglycoside antibiotics, neomycin and paromomycin. Aminoglycoside antibiotics are chosen
for this research study because, like macrolides, they function by blocking 50S subunit assembly.
However, unlike macrolides, aminoglycosides also block 30S subunit assembly (Campuzano and
others 1979; Foster and Champney 2008; Mehta and Champney 2002; Silvers and Champney
2005; Tenson and Mankin 2006). The E. coli mutants that are found in this study to have an
increased sensitivity to aminoglycosides are not found in nature. Therefore, I want to determine
if a RNase inhibitor can be used to mimic the enhanced antibiotic sensitivity of RNase mutant E.
coli cells. It is hypothesized that an inhibitor of ribonucleases can inhibit bacterial RNases and
potentiate the effects of both a macrolide antibiotic and an aminoglycoside antibiotic.
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Specific Research Aims
Aim 1: To determine whether RNase deficient Escherichia coli cells will display increased
sensitivity to aminoglycoside antibiotics. Results are found in Chapter 2
Frazier, A. D., and W. S. Champney. 2012. Inhibition of ribosomal subunit synthesis in
aminoglycoside treated ribonuclease mutants of Escherichia coli. Archives of
Microbiology:In Submission.

Aim 2: To determine whether the use of vanadyl ribonucleoside complex will potentiate the
effects of an aminoglycoside and a macrolide in wild type Escherichia coli cells. Results are
found in Chapter 3
“Inhibition of Ribosomal Subunit Synthesis in Escherichia coli by the Vanadyl
Ribonucleoside Complex”

Aim 3: To determine whether the use of vanadyl ribonucleoside complex will potentiate the
effects of an aminoglycoside and a macrolide in methicillin sensitive and methicillin resistant
Staphylococcus aureus cells. Results are found in Chapter 4
Frazier, A. D., and W. S. Champney. 2012. The vanadyl ribonucleoside complex inhibits
ribosomal subunit formation in Staphylococcus aureus. Journal of Antimicrobial
Chemotherapy:In Submission.
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CHAPTER 2

Inhibition of ribosomal subunit synthesis in aminoglycoside
treated ribonuclease mutants of Escherichia coli

Ashley D. Frazier and W. Scott Champney*
Department of Biochemistry and Molecular Biology
Quillen College of Medicine
East Tennessee State University
Johnson City, TN 37614 USA

*Corresponding author: Tel: 423-439-2022; Fax: 423-439-2030; E-mail: Champney@etsu.edu

Keywords: Escherichia coli; ribonuclease mutants; ribosome assembly; neomycin;
paromomycin
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Abstract The bacterial ribosome is a major target for current antibiotic therapy. During
ribosomal subunit biogenesis, ribonucleases (RNases) play an important role in rRNA
processing. Aminoglycoside antibiotics bind to both 30S and 50S subunits and stall subunit
assembly. E. coli cells deficient for specific RNases are predicted to have an increased
sensitivity to neomycin and paromomycin. It is shown that E. coli strains deficient for the rRNA
processing enzymes RNase III, RNase E, RNase R, RNase G, or RNase PH have enhanced
subunit assembly defects. These mutants showed an increased sensitivity to both aminoglycoside
antibiotics. An increase in 16S and 23S rRNA fragmentation was detected in E. coli cells
deficient for these enzymes. This research identified ribonucleases involved in rRNA processing
as important in the effectiveness of aminoglycoside inhibition.

41

Introduction
Resistance to the most commonly used antimicrobial agents is increasing. Well examined
mechanisms include acquisition of resistance genes, up-regulation of genes encoding cellular
efflux pumps and spontaneous mutations in target genes (Zinner 2007). Development of novel
antibacterial agents and the identification of additional bacterial targets have become important
research endeavors.
One important target of many antibiotics is the bacterial ribosome (Wallis and Schroeder
1997; Champney 2006). The prokaryotic ribosome consists of a large 50S and a small 30S
subunit. The 50S subunit is composed of 23S and 5S rRNA and 34 proteins. 30S subunits
contain 16S ribosomal RNA and 21 proteins. During subunit biogenesis, 16S, 23S, and 5S rRNA
transcripts and ribosomal proteins combine to form intermediate precursors. The rRNA in the
precursor particles is cleaved by endo- and exoribonucleases to produce the mature subunits
(Kaczanowska and Rydén-Aulin 2007; Deutscher 2009). In addition to maturation, ribonucleases
(RNases) are involved in degradation of rRNA. When an inhibitor, such as an antibiotic, is
introduced into a bacterial cell during ribosomal formation, specific RNases are utilized to
degrade the rRNA to eliminate the stalled precursor (Champney 2006).
Some antibiotics function by targeting both the 30S and 50S subunits. Neomycin and
paromomycin are two aminoglycoside antibiotics that have been shown to inhibit 30S subunit
assembly in various bacteria, including E. coli and Staphylococcus aureus (Mehta and
Champney 2002; Mehta and Champney 2003). These antibiotics bind to helix 44 of 16S rRNA
and stimulate mistranslation of mRNA. Aminoglycosides also bind to helix 69 of 23S rRNA. By
binding to helix 69, the ability of the ribosome recycling factor to recycle the ribosome is
inhibited. It can be postulated, based on previous research, that the binding of aminoglycosides
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to Helix 69 inhibits the ribosome recycling factor from dissociating the 30S and 50S ribosomal
subunits and recycling the ribosome (Hirokawa et al. 2005; Borovinskaya et al. 2007;
Scheunemann et al. 2010).
This important role of RNases in rRNA processing and subunit assembly makes these
enzymes potential targets for novel antibiotics. It has been previously shown that strains of E.
coli deficient for RNase E, RNase II, or polynucleotide phosphorylase (PNPase) displayed an
increased sensitivity to erythromycin or azithromycin (Usary and Champney 2001; Silvers and
Champney 2005). These mutant E. coli strains also demonstrated an accumulation of 23S rRNA
and a reduced rate of recovery when the antibiotic was removed. The importance of RNases in
rRNA processing led us to propose that mutant E. coli strains would also be more sensitive to
aminoglycosides. This work shows that E. coli strains deficient for RNase III, RNase E, RNase
R, RNase G, or RNase PH have an increased sensitivity to neomycin and paromomycin,
reflected in reduced subunit synthesis and enhanced rRNA turnover.

Materials and methods
Analysis of cellular growth and viability

Escherichia coli strains that were used are listed in Table 2.1. Cultures were grown at 37 oC (or
32oC for ts mutants) in tryptic soy broth (TSB). Strains SK5665, SK5729, SK6639 and SK7622
were supplemented with 4g/mL thymidine. Growth rates were measured as an increase in
cellular density over time using a Klett-Summerson colorimeter. At a Klett reading of 20,
neomycin or paromomycin at 5 or 10µg/mL were added to the appropriate cultures. At a Klett
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reading of 80, cellular viability was determined by TSB agar plate colony counting after serial
dilutions (Jett et al. 1997).

Analysis of ribosomal subunit assembly

Cell cultures were grown in TSB as described. At a Klett reading of 20, neomycin or
paromomycin at 5µg/mL were added to the appropriate cultures. After 15 minutes of growth
with the antibiotics, 3H uridine (30 Ci/mmol, Am. Radiochemicals) at a concentration of
1µCi/mL and uridine at a concentration of 2µg/mL were added. The cells were allowed to grow
for two cellular doublings. At that time, uridine was added to 50µg/mL and the cells were
incubated for an additional 15 minutes. Cells were collected by centrifugation and stored frozen
at -70oC.
Cellular lysates were prepared with lysozyme and DNaseI as previously described (Silvers
and Champney 2005). The samples were centrifuged through 5-20% sucrose gradients in S
buffer in an SW41 rotor at 187813 x g for 3.5 hours. Following centrifugation, fractions were
collected by pumping them through an ISCO Model UA-5 absorbance monitor set at 254nm. The
fractions were collected into vials and mixed with 3mL Scintisafe gel before measuring the 3H
uridine radioactivity by liquid scintillation counting.

Analysis of total cellular RNA with the Agilent Bioanalyzer

Bacterial cells were grown as described above. At a Klett reading of 80 or an approximate
density of 4x108 cells/mL, the cells were collected by centrifugation and RNA was extracted
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from the cell pellet. Total RNA from cell samples was isolated by phenol/chloroform extraction
and ethanol precipitation (Rio et al. 2011). Typically 0.5 to 1µg of RNA was examined using an
Agilent Bioanalyzer 2100 and the RNA 6000 nano chip.

Table 2.1 E. coli strains used in this study
Strain
SK901
D10-1
SK7622
SK5665
SK4803
N7060

Genotype

Reference or source

None
I
III
E
II

F- malA thiHfrH met- rna-1 relA
F-thyA715 rncD38::kanR
F-thyA715 rne1
F-gal thi ton sup hasdR4 endAsbcB15 rnb296
F- metB1 tryA451 rpsl478 rna919rnb464
pnp13
∆rna ∆rnr::cam
F- zce-726::Tn10, TetR, rng::cat CmR
F-thyA715, CmR, pnp-200, rph-1, λF- thyA715, rna-19, rnb-500, pnp-7, λ-,
rph-1

(Kushner et al. 1977)
(Gesteland 1966)
(Babitzke et al. 1993)
(Arraiano et al. 1988)
(Donovan and Kushner 1986)

I, II, PNPase
-

-

MG1655 I R
GW11
SK6639
SK5729

Phenotype

I, R
G
PNPase
I, II, PNPase, PH

(Weatherford et al. 1972)
(Chen and Deutscher 2010)
(Li et al. 1999)
(Cheng and Deutscher 2003)
Sidney Kushner

Analysis of 16S rRNA and 23S rRNA by Northern blot hybridization

Biotinylated 16S and 23S specific probes were constructed as previously described (Silvers and
Champney 2005). The 16S (241 bp) and 23S (146 bp) DNA probes were amplified from plasmid
pKK3535 DNA (Brosius et al. 1980) using the polymerase chain reaction. The 23S primers used
were 23S F: TAG GGG AGC GTT CTG TAA G and 23S R: CCC ATT AAC GTT GGA C (nt.
nos. 1188-1334). The 16S primers used were 16S F: GGA GGA AGG TGG GGA TGA CG and
16S R: ATG GTG ACG GGC GGT GTG (nt. nos. 1173-1414). The primers were from Life
Technologies. PCR products were purified by extraction with equal amounts of phenol and
chloroform before precipitating with 2 volumes of ethanol. The pellets were resuspended in
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30µL of sterile water. The purified DNA probes were labeled with biotin using the Label-IT
biotin labeling kit (Mirus) per the manufacturer’s instructions (Silvers and Champney 2005).
Six micrograms of total RNA was denatured by heating at 55 oC for 10 minutes and
separated on a 5% TAE PAGE gel as previously described (Rio et al 2011). After destaining
overnight in sterile water, RNA was transferred onto Nytran nylon membranes using a Turbo
blot apparatus (Schleicher & Schuell). The membranes were pre-hybridized in 15mL of 1X prehybridization solution (MRC, Inc.) at 42oC for 30 minutes. The membranes were then hybridized
overnight at 42oC with 6mL hybridization buffer (50% formamide, 5X SSC, 0.1% sarkosyl,
0.02% SDS and 200µg/mL BSA), 1X background quencher (MRC, Inc.), and 4pmol of the
denatured 16S or 23S specific probe (Silvers and Champney 2005). After hybridization, the
membranes were washed and the probe detected with horseradish peroxidase using the
North2South chemiluminescent hybridization kit (Pierce Chemical Co.). Analysis of the rRNA
fragmentation was conducted by image analysis in the G Box Imager (SynGene).

Statistical analysis

Statistical differences were determined using Student t-test. Each wild type or RNase
deficient mutant sample incubated with an antibiotic was compared to the control cells without
antibiotics for that RNase strain. In each table, an asterisk indicates a statistical significance of
P<0.05.
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Results
An initial test was performed to determine whether E. coli mutants deficient for any of eight
RNases would show an enhanced sensitivity to the aminoglycosides, neomycin and
paromomycin. Previous research has shown that strains missing RNase II, E or PNPase
demonstrated an increased sensitivity to the macrolide antibiotic azithromycin (Silvers and
Champney 2005). As Table 2.2 shows, strains missing the rRNA processing enzymes RNase III,
E, R, G or PH revealed a large reduction in viability after growth with either aminoglycoside. All
the percentages were determined by comparing the antibiotic treated samples with that strain’s
control. In particular, neomycin at 10µg/mL reduced the viability of RNase III, E, R, or PH
mutants to approximately 10% of the untreated control strain (Table 2.2).

Table 2.2 Effect of aminoglycosides on viability of wild type and mutant E. coli cells

Strain

RNase mutation

SK901
D10-1
SK7622
SK5665
SK4803
N7060
MG1655 I-RGW11
SK6639
SK5729

None
I
III
E
II
I, II, PNPase
I, R
G
PNPase
I, II, PNPase, PH

% Control total viable cell count
Neomycin
Paromomycin
5µg/mL
10µg/mL
5µg/mL
10µg/mL
15.4±12.8
26.3±9.0
7.7±5.1
3.0±0.5 *
18.2±5.0
14.2±4.1
20.7±19.8
17.4±17.4
0.32±0.001 *
5.7±4.2 *
4.6±3.5 *
2.5±1.2 *
51.9±33.4
3.6±0.4 *
12.5±8.4 *
0.89±0.001 *
44.4±25.9
5.2±4.9
11.1±3.3
1.1±0.9
5.2±5.0 *
6.1±2.4 *
33.5±15.8
3.3±0.2 *
13.4±7.5 *
11.5±7.3 *
5.1±1.5 *
4.2±0.4 *
10.6±7.1 *
23.2±8.8 *
10.7±6.3 *
2.4±0.9 *
75.4±21.1
5.2±1.8 *
51.4±4.9
3.2±0.7 *
80.0±39.3
3.0±1.9 *
15.0±6.1 *
2.0±0.6 *

Results are the means ± standard error of 4 independent experiments. (*) statistically significant
with a P value <0.05
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Aminoglycoside antibiotics can bind to both 30S and 50S ribosomal subunits (Borovinskaya
et al. 2007; Scheunemann et al. 2010). Therefore, the mutants deficient for RNase I, E, III, R, G,
PH or a combination of mutations were examined for impaired 30S and 50S ribosomal subunit
assembly. E. coli deficient for more than one mutation (N7060) were also included in
determining impairment of 30S and 50S ribosomal subunit assembly. This is because we wanted
to show that the decrease in 30S and 50S subunit assembly for MG1655 I -R- and SK5729 was
due to RNase R and RNase PH deficiencies respectively. Cells were labeled with 3H-uridine
during growth without and with antibiotics. Ribosomal subunit amounts were measured after
separation by sucrose gradient centrifugation. Figure 2.1 shows the gradient profiles for each
selected strain. Both aminoglycosides promoted a reduction in 30S subunit amounts in most of
the RNase mutant E. coli strains. 50S subunit levels were reduced in every case after drug
treatment except in the wild type and RNase G deficient strains. Significantly, a major increase
in labeled RNA was seen in the top gradient fractions (Table 2.3), indicative of rRNA
degradation (Silvers and Champney 2005). For example the RNase E mutant strain showed a 14
and 24% increase in labeled RNA at the top of the gradient when neomycin or paromomycin
where added at a concentration of 5µg/mL. E. coli deficient for RNase PH showed a 10%
decrease in the 30S ribosomal subunit when either antibiotic was added. Additionally, the 50S
ribosomal subunit was decreased by 5 and 13% when 5µ/mL neomycin or paromomycin were
added. In every case, the labeled RNA lost from the subunits was accounted for by an
approximate amount present in the top gradient region. Strain N7060 is deficient for RNases I, II,
and PNPase. Due to the findings that this strain displayed a decrease in 30S and 50S ribosomal
subunits (Table 2.3), it was determined that any statistical significance found in strain SK5729 is
due to the loss of RNase PH and not to the other mutations.
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Fig. 2.1 Sucrose gradient profiles of 3H uridine labeled ribosomal subunits isolated from E. coli
cells grown with or without 5µg/mL antibiotics. Gradient profiles for wild type (A), RNase III
deficient (B), RNase E deficient (C), RNase R deficient (D), RNase G deficient (E), and RNase
PH deficient (F)
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Table 2.3 Distribution of 3H uridine labeled RNA in sucrose gradient regions
% Total gradient radioactivity
Strain

RNase
mutation

Control

Neomycin

Top

30S

50S

SK901

None

29.01±0.5

24.84±1.1

43.09±0.3

D10-1

I

27.92±3.1

22.94±0.8

45.57±1.8

SK7622

III

23.99±1.3

23.84±0.5

48.70±.05

SK5665

E

31.55±0.9

23.97±0.4

40.57±1.4

N7060

I, II, PNPase

25.60±1.6

25.41±0.06

46.15±2.9

MG1655I-R-

I, R

30.28±1.0

24.37±0.4

41.56±1.5

GW11

G

29.04±2.4

24.75±1.5

43.38±1.6

SK5729

I, II,
PNPase, PH

38.31±1.9

26.42±3.8

31.78±2.6

Top
47.52±0.5
(166.8) *
45.52±5.0
(163.0)
44.06±6.3
(187.0)
47.61±6.6
(150.9)
37.12±2.7
(145.0)
44.98±6.2
(148.5)
42.28±1.8
(145.6) *
62.42±4.4
(162.9) *

30S
24.63±1.3
(105.9)
22.49±2.0
(105.1)
23.73±3.2
(99.5)
20.07±1.0
(83.7)*
22.20±1.1
(87.4)
22.05±1.9
(90.5)
19.79±0.8
(80.0)
16.85±0.7
(63.8)

Paromomycin
50S
20.27±1.0
(47.0) *
27.55±8.4
(62.8)
24.93±3.9
(51.2) *
27.83±5.5
(68.6)
36.92±3.9
(80.0)
28.76±5.4
(69.2)
26.48±2.8
(61.0)
16.47±3.6
(51.8) *

Top
42.80±2.2
(149.2) *
40.32±8.6
(146.7)
41.95±2.7
(176.7) *
37.64±3.8
(119.3)
24.78±1.8
(96.8)
34.40±2.9
(113.6)
33.34±1.7
(114.8)
62.03±3.0
(161.9) *

30S
23.74±0.7
(95.6)
19.32±3.2
(84.2)
22.57±1.1
(94.7)
27.12±4.5
(113.1)
21.50±0.1
(84.6)*
24.32±0.9
(99.8)
23.74±0.005
(95.9)
17.31±1.0
(65.5)

50S
27.85±0.5
(66.9) *
35.49±6.1
(79.7)
30.37±3.2
(62.4) *
33.78±2.6
(83.3)
45.77±0.06
(99.2)
37.48±4.0
(90.2)
40.00±2.1
(92.2)
15.46±2.3
(48.6) *

Cells were grown with 5µg/mL aminoglycosides. Radioactivity in gradient fractions corresponding to the top, 30S, and 50S regions
were summed and calculated as a percent of the total radioactivity in the gradients. Percentage of the 30S and 50S regions in
comparison to the mutant or wild type strain controls is shown. Results are the means ± standard error of 2 independent experiments.
(*) statistically significant with a P value <0.05
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Total RNA was isolated from each selected strain after growth without and with the
aminoglycosides, and the status of rRNA in all cells was examined by Agilent chip analysis. An
enhanced rRNA degradation was observed in the mutants, particularly after growth with the
antibiotics at 10µg/mL (Figure 2.2 and Table 2.4). In addition, RNase R and RNase PH mutant
strains displayed an increase in small RNA oligonucleotides. As with the gradient rRNA
distribution, the loss of 16S and 23S rRNA could be accounted for by an increase in small RNA
species. For example, the RNase PH mutant strain’s small RNA was increased by more than
130% when either antibiotic was added at 10µg/mL. In the RNase R mutant strain, 16S rRNA
was decreased by 19-23% when neomycin or paromomycin were added at a concentration of
10µg/mL. The RNase PH deficient strain showed a 35% and 16% decrease in 23S rRNA when
either neomycin or paromomycin were added at a 10µg/mL concentration (Table 2.4). Finally,
the analysis revealed the accumulation of a band the approximate size of 16S precursor RNA in
all mutant strains with the exception of the RNase G deficient strain. This 16S precursor band
can be seen directly above the 16S band in the Agilent gel image (Figure 2.2).
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Fig. 2.2 Agilent gel analysis of total RNA. RNA samples were analyzed by the Agilent
Bioanalyzer. Agilent chip analysis of RNA from wild type and mutant cells grown with 5µg/mL
antibiotics (a) and (b). Agilent chip analysis of RNA from wild type and mutant cells grown with
10µg/mL antibiotics (c) and (d). Control (C), Neomycin (N), Paromomycin (P)
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Table 2.4 Percentage distribution of small, 16S, and 23S rRNA by Agilent gel analysis
% Total area
Strain

RNase
mutation

SK901

None

SK7622

III

SK5665

E

MG1655
I-RGW11

I, R

SK5729

I, II,
PNPase,
PH

Strain

RNase
mutation

SK901

None

SK7622

III

SK5665

E

MG1655
I-RGW11

I, R

SK5729

I, II,
PNPase,
PH

G

Control

Neomycin 5µg/mL

Paromomycin 5µg/mL

RIN

Small

16S

23S

RIN

Small

16S

23S

RIN

Small

16S

23S

9.8±
0.1
8.8±
1.1
8.8±
0.8
9.1±
0.5
9.7±
0.1
6.6±
0.005

11.53±
4.4
17.87±6.6

26.80±1.3

40.80±3.2

29.73±3.3

44.27±5.3

17.50±6.9

22.85±3.6

36.60±6.7

13.80±3.4

19.80±2.4

32.57±6.7

18.00±2.3

23.50±1.0

34.47±1.8

24.20±0.2

14.40±0.1

19.35±0.7

9.5±2.3
(96.9)
8.8±1.0
(100.0)
9.3±0.3
(105.7)
8.2±0.8
(90.1)
9.4±0.1
(96.9)
7.0±0.1
(106.1) *

17.37±4.7
(150.7)
12.80±5.3
(71.6)
15.10±5.3
(86.3)
15.83±3.5
(114.7)
17.03±3.7
(94.6)
29.70±0.2
(122.7) *

23.03±1.3
(85.9)
30.93±5.2
(104.0)
24.00±2.8
(105.0)
15.50±4.7
(78.3)
21.33±0.7
(90.8)
15.65±0.1
(108.7) *

38.87±2.7
(95.3)
46.73±4.1
(105.6)
37.38±4.1
(102.1)
26.07±8.3
(80.0)
33.37±1.6
(96.8)
20.10±0.3
(103.9)

8.7±0.8
(88.5)
9.2±0.7
(104.5)
9.3±0.3
(105.7)
9.0±0.1
(98.9)
8.5±0.9
(87.6)
6.8±
0.005
(103.0) *

18.83±3.2
(163.3)
14.90±3.1
(83.4)
19.18±7.0
(109.6)
17.57±1.2
(127.3)
20.73±3.8
(115.2)
34.90±2.0
(144.2) *

23.78±1.4
(88.7)
37.37±11.2
(125.7)
25.55±2.0
(111.8)
19.77±1.3
(99.8)
17.97±4.3
(76.5)
12.70±0.1
(88.2) *

34.70±1.9
(85.0)
33.97±8.9
(76.7)
39.70±2.8
(108.5)
33.23±2.8
(102.0)
26.70±6.9
(77.5)
15.25±0.3
(78.8) *

% Total area

G

Control

Neomycin 10µg/mL

Paromomycin 10µg/mL

RIN

Small

16S

23S

RIN

Small

16S

23S

RIN

Small

16S

23S

9.5±
0.2
9.0±
0.4
10.0±
0.1
9.9±
0.1
9.8±
0.1
6.7±
0.1

12.05±0.2

24.40±1.0

42.10±3.7

16.25±1.5

23.35±0.9

32.50±1.0

6.60±0.4

27.70±1.0

48.10±5.6

13.8±1.4

25.4±0.5

43.65±2.65

18.45±2.8

23.65±1.2

34.80±0.6

23.50±0.7

13.50±0.7

19.05±0.5

9.8±0.2
(103.4)
7.7±1.4
(85.6)
9.2±0.005
(92.0)
8.9±0.1
(89.9)
9.6±0.3
(98.0)
6.1±
0.005
(91.0) *

13.70±0.7
(113.7)
20.55±1.1
(126.5)
5.10±0.9
(77.3)
13.05±0.3
(94.6)
15.65±3.3
(84.8)
33.60±0.5
(143.0) *

26.85±4.55
(110.0)
23.50±1.5
(100.6)
23.8±0.8
(85.9)
20.55±0.1
(80.9) *
21.80±1.1
(92.2)
9.45±0.3
(70.0) *

44.25±4.5
(105.1)
38.90±9.8
(119.7)
40.85±2.8
(84.9)
40.80±1.3
(93.5)
34.80±2.9
(100.0)
12.70±0.4
(65.1) *

8.8±1.3
(92.6)
9.4±0.2
(104.4)
9.3±0.1
(93.0)
9.0±0.1
(90.9)
9.8±0.3
(100.0)
6.7±0.1
(100.0)

20.10±3.7
(166.8)
17.10±0.1
(105.2)
9.45±1.1
(143.2)
16.95±0.1
(122.8)
15.20±1.0
(82.4)
31.30±0.2
(133.2) *

28.00±3.2
(114.8)
23.25±0.6
(99.6)
22.65±0.9
(81.8)
19.65±0.4
(77.4) *
25.4±2.0
(107.4)
13.35±0.3
(98.9)

44.00±3.6
(104.5)
34.00±4.5
(104.6)
37.80±2.2
(78.6)
40.50±1.9
(92.8)
40.15±2.3
(115.4)
15.95±0.2
(83.7) *

Total RNA in gel bands from Figure 2.2 was computed by analysis of the electropherograms using Agilent software. Percentage of the
total RNA in comparison to the wild type or mutant strain controls in each gel region is shown. The RNA integrit y number (RIN) is
indicated. Results are the means ± standard error of 2 independent experiments. (*) statistically significant in comparison to no drug
controls for each strain with a P value <0.05
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Degradation of 16S and 23S rRNA stimulated by antibiotic treatment was further examined
by Northern hybridization analysis. Figure 2.3 shows the result of Northern blots hybridized with
a 16S rRNA probe, and Figure 2.4 shows the same E. coli samples examined for rRNA
fragmentation with a 23S rRNA probe. With the exception of the RNase E mutant, enhanced 16S
rRNA fragmentation was observed (Figure 2.3). Enhanced 23S rRNA fragmentation was also
detected by Northern hybridization analysis for the RNase III, R and PH deficient strains after
antibiotic treatment (Figure 2.4). A measurement of the fragment sizes was determined for both
16S and 23S rRNA by G box Analysis (Figure 2.3 and Figure 2.4). These results substantiate the
observations made by sucrose gradient and gel analysis of rRNA degradation.
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Fig. 2.3 Northern hybridization analysis of 16S rRNA fragmentation for wild type and RNase
mutant E. coli cells. RNA was isolated from cells grown as indicated with 10µg/mL
aminoglycosides. RNA sequences were identified by hybridization with a 16S DNA probe and
nucleotide sizes are indicated. Control (C), Neomycin (N), Paromomycin (P)
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Fig. 2.4 Northern hybridization analysis of 23S rRNA fragmentation for wild type and RNase
mutant E. coli cells. RNA was isolated from cells grown as indicated. RNA was isolated from
cells grown as indicated with 10µg/mL aminoglycosides. RNA sequences were identified by
hybridization with a 23S DNA probe and nucleotide sizes are indicated. Control (C), Neomycin
(N), Paromomycin (P)

Discussion
Aminoglycosides are a widely used family of antibiotics that target the bacterial ribosome
(Sutcliffe 2005). They bind to both subunits of the ribosome and affect both translational
accuracy and ribosomal subunit recycling. Neomycin and paromomycin are structurally similar
compounds and interact with the subunit rRNAs in similar ways. Both antibiotics stall the
assembly of the 30S subunit in addition to impairing translation (Champney 2006).
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Ribonucleases function in rRNA processing and degradation (Deutscher 2009). RNases III,
E, G, and PH are involved in the processing of precursor rRNA during subunit synthesis. RNase
III is responsible for the initial cleavage of the precursor rRNA (Deutscher 2009). RNase G and
E function in processing of the 5’ end of 16S rRNA (Li et al. 1999). Additionally, RNase G and
PH are involved in processing of 23S rRNA (Song et al. 2011; Gutgsell and Jain 2012). RNase
III, RNase E, and RNase PH are also involved in rRNA degradation in addition to RNase II, R,
and PNPase (Deutscher 2009; Arraiano et al. 2010). RNase E, PNPase, enolase, and the DEADbox helicase Rh1B form a complex known as the degradosome. The degradosome is responsible
for degradation of rRNA under some circumstances (Vanzo et al. 1998). RNase R initiates rRNA
degradation by binding to a 3’ terminus overhang (Vincent and Deutscher 2006).
Elimination of specific RNases by mutation is predicted to enhance the effectiveness of
antibiotics which stall ribosomal subunit formation by reducing the ability to recycle ribosomal
subunits. E. coli cells with a mutation in RNase E showed enhanced sensitivity to erythromycin
and the accumulation of a precursor to the 50S subunit (Usary and Champney 2001). E. coli cells
deficient for RNase II or PNPase showed an enhanced sensitivity to azithromycin and an
impairment of 23S rRNA function. Turnover of the RNA was stimulated and 50S ribosomal
subunit formation was impaired by azithromycin treatment. In addition, recovery of subunit
formation after antibiotic removal was impaired (Silvers and Champney 2005). Based on these
findings, it was hypothesized that E. coli cells deficient for specific RNases would display an
increased sensitivity to aminoglycosides.
The enzymes identified in this study to affect sensitivity to aminoglycosides are, for the
most part, different from the enzymes shown to affect erythromycin and azithromycin sensitivity
(RNase E and RNase II and PNPase). The difference in RNases in the two cases may result from
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the differences in the effects of macrolides and aminoglycosides on the subunit assembly
sequence. In this study, E. coli deficient for RNases III, E, R, G, or PH displayed an increased
sensitivity to neomycin or paromomycin. Aminoglycosides affect both 30S and 50S ribosomal
subunit synthesis while macrolides only affect 50S ribosomal subunit assembly (Champney and
Tober 2000; Usary and Champney 2001; Mehta and Champney 2002). During transcription, 16S
rRNA is transcribed first and initiates 30S precursor assembly prior to 23S and 5S rRNA
synthesis for 50S precursor formation. Aminoglycoside antibiotic stalling of 30S formation
leads to the accumulation of a 21S precursor, whose rRNA will not be further processed in
specific RNase deficient mutants. Macrolide antibiotic stalling of 50S assembly generates a 32S
precursor to the 50S particle which would need to be removed by the rRNA degradative enzymes
RNase II and PNPase as observed (Silvers and Champney 2005).
The somewhat larger effects of the aminoglycosides on subunit synthesis and rRNA
degradation in strain SK5729 may be due to additional RNase mutations in this strain. The strain
lacks RNases I, II, PH and PNPase. However, examination of a mutant strain (N7060) deficient
for RNase I, II, and PNPase showed no significant effects on subunit synthesis or rRNA
degradation in the presence of either aminoglycoside (A. F. unpublished). We would conclude
that the aminoglycoside effects in SK5729 are therefore likely due to the loss of RNase PH and
not to the lack of the other ribonucleases.
In summary, this research has identified rRNA processing RNases as important in the
effectiveness of aminoglycoside antibiotic inhibitory activity. Inhibition of processing RNases by
small molecule inhibitors or RNA interference methods could represent an attractive new
antimicrobial target.
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ABSTRACT
The increase in antibiotic resistant microorganisms has driven a search for new antibiotic
targets and novel antimicrobial agents. A large number of different antibiotics target
bacterial ribosomal subunit formation. Several specific ribonucleases are important in the
processing of rRNA during subunit biogenesis. This work demonstrates that the
ribonuclease inhibitor, vanadyl ribonucleoside complex (VRC), can inhibit RNases
involved in ribosomal subunit formation. The ribosomal subunit synthesis rate was
significantly decreased and ribosomal RNA from the subunit precursors was degraded.
VRC had no inhibitory effect on translation. VRC also enhanced the inhibitory effects of
an aminoglycoside and a macrolide antibiotic.

*Corresponding author. Phone: (423) 439-2022. Fax: (423) 439-2030. E-mail:
Champney@etsu.edu

Keywords: vanadyl ribonucleoside complex; Escherichia coli; ribosome assembly; protein
synthesis
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INTRODUCTION
The increase in antibiotic resistance is a global threat to both physicians and scientists (30). An
important area of investigation is to discover novel antimicrobial agents to which resistance has
not yet been developed. In addition, a significant effort is being made to identify new cellular
targets for drug discovery (1, 4, 19).
The bacterial ribosome is a target for a diverse collection of different antibiotics (9, 36).
Drug binding sites and molecular mechanisms of action have been described recently for many
of these compounds based on refined crystal structures (7, 9, 14, 15, 25, 34). Most of these
antibiotics bind to the 30S or 50S ribosomal subunit and inhibit translation of mRNA.
Importantly, biogenesis of the subunits is an additional cellular target for many of these agents
(8). When synthesis of either subunit is inhibited, specific ribonucleases (RNases) proceed to
degrade the rRNA in the ribosomal subunit assembly intermediates (9). In particular, RNase E is
important in the turnover of a 50S subunit precursor particle present in erythromycin-inhibited
cells (34) and the enzymes RNase II and PNPase are also involved in rRNA degradation in cells
inhibited by azithromycin (31).
In Escherichia coli cells, at least five different RNases are needed to generate and process
the 5’ and 3’ ends of 16S, 23S and 5S rRNA (18, 23, 32, 35). Subunit assembly intermediates are
the substrates for these activities. Mutant organisms missing any of these proteins show an
enhanced sensitivity to both paromomycin and neomycin (16). These observations suggest that
RNases in E. coli cells could be novel targets for antimicrobial agents. Inhibition of certain
RNases is predicted to enhance the inhibitory effects of antibiotics targeting subunit formation
(31, 34).
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The vanadyl ribonucleoside complex (VRC) is a low molecular weight inhibitor of
RNases that is commonly used during the isolation of RNA from cells (2, 28, 29). Although its
target specificity is unknown, the compound is thought to target endoribonucleases (2). VRC has
been shown to reduce the synthesis of both ribosomal subunits in Staphylococcus aureus (17).
Cell viability was reduced in this organism and rRNA degradation was stimulated. The
compound also enhanced the inhibitory effects of both paromomycin and azithromycin.
We hypothesized that VRC could therefore function as a novel antimicrobial agent in a
gram negative organism, like E. coli. This work shows that VRC caused an inhibitory effect on
ribosomal subunit formation in E. coli cells without affecting bacterial protein synthesis rates.
VRC also enhanced the growth inhibitory effects of paromomycin and azithromycin in these
cells. This work indicates that inhibition of RNases is a new drug target.

MATERIALS AND METHODS
Cellular growth and viability. Escherichia coli strain SK901 (22) cells were grown in a 37oC
water bath in tryptic soy broth (TSB). After 10 minutes of initial bacterial growth, 5mM vanadyl
ribonucleoside complex (VRC, New England Biolabs) was added to the cells. Paromomycin or
azithromycin were added to some cultures at concentrations of 5µg/mL or 10µg/mL. The cells
were grown for two cellular doublings to approximately 4x108 colony forming units (CFU)/mL.
VRC caused a color change to the TSB media used here which made an estimate of the growth
rate by turbidity changes difficult. Growth rates were measured as an increase in cell number
with time after serial dilution and plating on TSB agar plates as previously described (20).
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Rate of protein synthesis. Bacterial cultures were grown as above in the presence or absence of
0.5, 1, or 5mM VRC. After two cellular doublings, 1µCi/mL of 35S-methionine (1175 Ci/mmol,
MP Biomedicals) was added. Following the addition of the radioisotope, three 0.2mL samples
were removed at 5 min intervals. Samples were precipitated in 10% TCA with 100µg of BSA,
collected and washed on Whatman GF/A glass fiber filters. The filters were placed into vials
containing 3mL Scintisafe gel. Radioactivity was measured by liquid scintillation counting.
Ribosomal subunit assembly. Cells were grown as described above. Following the addition of
5mM VRC at a Klett of 20, paromomycin, or azithromycin were added to the appropriate
cultures. After 15 minutes of growth with the antibiotics, 3H-uridine at 1µCi/mL (30 Ci/mmol,
Am. Radiochemicals) and uridine at 2µg/mL were added. After the cells had grown through two
doublings, 50µg/mL of uridine was added and the cells were incubated an additional 15 min.
Cells were collected by centrifugation and were stored frozen at -70°C.
Cellular lysates were prepared by a lysozyme-freeze thaw method as previously described
(14). The lysates were centrifuged through 5-20% sucrose gradients in S buffer in an SW 41
rotor at 187813 x g for 3.5 hours (31). Following centrifugation fractions were collected after
pumping through an ISCO Model UA-5 absorbance monitor set at 254nm. The fractions were
collected into vials and mixed with 3mL Scintisafe gel before measuring the radioactivity by
liquid scintillation counting.
Uridine pulse and chase labeling. Cell cultures of 12ml were grown to a Klett of 20 and then
5mM VRC was added. Following one cellular doubling, the cells were pulse labeled with 3Huridine (1µCi/ml) for 90 sec and then chased with uridine at a concentration of 25µg/ml. At six

66

time intervals, 2ml samples were removed, collected by centrifugation, and stored frozen before
analysis by sucrose gradient centrifugation as previously described (12, 31).
Agilent Bioanalysis of RNA. Bacterial cells were grown as described above. At a density of
4x108 cells/mL, the cells were collected by centrifugation and RNA was extracted from the cell
pellet using a chloroform/phenol extraction procedure as detailed by a published method (29).
Total RNA was examined using an Agilent Bioanalyzer 2100 and the RNA 6000 chip. The
sample preparation, loading procedure and run was carried out according to manufacturer’s
instructions for total RNA analysis. Generally 0.5 to 1µg of RNA was examined.
Northern blot hybridization. Biotinylated 16S and 23S specific probes were constructed by
PCR as previously described (31). The 16S (241 bp) and 23S (146 bp) DNA probes were
amplified from plasmid pKK3535 DNA (3) using the polymerase chain reaction with primers
from Life Technologies. The 23S primers used were (23S F) TAG GGG AGC GTT CTG TAA
G and (23S R) CCC ATT AAC GTT GGA C (nt. nos. 1188-1334). The 16S primers used were
(16S F) GGA GGA AGG TGG GGA TGA CG and (16S R) ATG GTG ACG GGC GGT GTG
(nt. nos. 1173-1414). PCR products were purified by extraction with phenol and chloroform and
precipitation with 2 volumes of ethanol. The pellets were resuspended in 30µL of sterile water.
The purified DNA probes were labeled with biotin using the Label-IT biotin labeling kit (Mirus)
(31).
Six micrograms of total RNA was denatured by heating at 55oC for 10 minutes and
separated on a 5% TAE PAGE gel as previously described (29). RNA was transferred from the
gel onto Nytran nylon membranes using a Turbo blot apparatus (S&S). The membranes were
pre-hybridized in 15mL of 1X pre-hybridization solution at 42oC for 30 minutes. The membranes
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were then hybridized overnight at 42oC with 6mL hybridization buffer, 1X background
quencher, and 4pmol of the denatured 16S or 23S specific probe as previously described (31).
After hybridization, the membranes were washed and the probe detected via the
North2South chemiluminescent hybridization kit (Pierce Chemical Co.) with strepavidinconjugated horseradish peroxidase. Quantitative analysis of the rRNA fragmentation was
determined by the G Box image analysis system (SynGene).
Statistical analysis. Statistics differences were determined by Student t-test. Each antibiotic or
VRC sample was compared to the control cells without VRC or antibiotics. In each table, an
asterisk indicates a statistical significance on P<0.05.

RESULTS
We have shown previously that 5mM VRC reduced the viability of S. aureus cells by over
90% and the compound also enhanced the effectiveness of two antibiotics in this microorganism
(17). The effects of VRC and the same antibiotics on growth of E. coli cells were determined by
colony counting of cell samples. E. coli cells grown with 5mM VRC alone showed a decrease in
the viable cell counts or CFU (Table 3.1). Azithromycin alone led to an approximate 60%
reduction in CFU; however, the inhibitory activities of azithromycin were enhanced in the
presence of 5mM VRC. This inhibition was seen as an additive effect of the VRC. Paromomycin
alone showed a significant decrease in the viable cell numbers, while the addition of VRC and
paromomycin led to an increase in cell numbers comparable to the control cells without
antibiotics or VRC (Table 3.1).
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TABLE 3.1 VRC effects on cellular antibiotic sensitivity
CFU (x107/mL)
101±11.2
8±1.0 (7.9) *
40±5.2 (39.6) *
87±7.9 (86.1)
126±10.2 (124.8)
18±2.4 (17.8) *

Control
Paromomycin
Azithromycin
Control + VRC
Paromomycin + VRC
Azithromycin + VRC

The percentage reduction in viability compared with the control cells for each strain is listed in
parenthesis. Antibiotics were used at 5µg/mL. Results are the means ± standard error of 3
independent experiments. (*) statistically significant with a P value <0.05

Based on the prior work in S. aureus (17), we tested whether the addition of VRC would
lead to a decrease in ribosomal subunit amounts in E. coli cells. The distribution of 3H-uridine
labeled rRNA after sucrose gradient centrifugation was used to examine 30S and 50S subunit
levels (Fig. 3.1a). Substantial reductions in the amounts of both particles were seen (Table 3.2).
The addition of 5mM VRC led to a 26% reduction in 30S and a 45% reduction in 50S subunit
levels (Table 3.2). In addition, a 26% increase in radio-labeled RNA was seen in the top gradient
fractions, indicative of rRNA degradation (31). The increase was proportional to the loss of
rRNA from both subunits (24%).
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FIG 3.1 Sucrose gradient profiles of 3H uridine labeled ribosomal subunits. Gradient profile for
subunits from cells grown without and with VRC (a). Gradient profile for subunits from cells
grown with VRC and 5µg/mL paromomycin (b). Gradient profile for subunits from cells grown
with VRC and 5µg/mL azithromycin (c). Note the differences in the left (without VRC) and right
(with VRC) axis.

TABLE 3.2 Distribution of ribosomal subunits in sucrose gradient regions

Treatment
Control
Paromomycin
Azithromycin
Control + VRC
Paromomycin + VRC
Azithromycin + VRC

% Total gradient radioactivity
Top gradient region
30S region
29.09±2.6
23.83±0.7
38.34±4.3 (131.8)
32.12±7.1 (134.8) *
42.45±7.6 (145.9)
30.74±4.1 (129.0) *
55.99±2.2 (192.5) *
17.84±1.5 (74.9) *
71.33±2.6 (245.2) *
12.29±2.6 (51.6) *
61.90±1.8 (212.8) *
23.4±1.40 (98.2)

50S region
41.19±2.5
24.92±3.7 (60.5) *
22.27±3.5 (54.1) *
22.66±1.6 (55.0) *
13.89±2.4 (33.7) *
10.05±0.3 (24.4) *

Cells were grown in the presence of 5µg/mL paromomycin or azithromycin and 5mM VRC.
Radioactivity in gradient fractions corresponding to the top, 30S, and 50S regions was summed
and calculated as a percent of the total radioactivity in the gradient. Percentage of the differences
in the 30S and 50S regions in comparison to the control is shown. Results are the means ±
standard error of 2 independent experiments. (*) statistically significant with a P value <0.05
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When 5µg/mL of paromomycin or azithromycin was added to the bacterial cells, 30S and
50S subunit assembly was impaired (Fig. 3.1; Table 3.2). Degradation of rRNA was stimulated
by both compounds (Fig. 3.1b, 3.1c). The addition of VRC in combination with the antibiotics
led to a further reduction in 30S and 50S subunit amounts and an enhancement in rRNA
degradation (Table 3.2). For example, when E. coli cells were incubated with 5µg/mL
azithromycin there was a 129% increase in the 30S subunit assembly, a 46% reduction in the 50S
subunit assembly and a 146% increase in the top of the gradient radio-labeled RNA. The increase
in 30S subunit assembly could be attributed to an increase in the 50S precursor, 32S. When the
E. coli cells were also incubated with 5mM VRC, there was a 2% reduction in 30S subunit
assembly, a 76% reduction in 50S subunit assembly, and a 213% increase in the top of the
gradient radio-labeled RNA compared to that of the untreated control cells. The proportional
increase in RNA degradation was seen in each instance (Table 3.2). Table 3.3 shows the net
reduction in the amounts of both subunits resulting from VRC inhibition alone and in
combination with each antibiotic.

TABLE 3.3 Inhibition of subunit synthesis by VRC and antibiotics
% Control amount
Treatment
Control
Control + VRC
Paromomycin + VRC
Azithromycin + VRC

30S
100.0±13.3
43.1± 8.1 *
18.6±14.3 *
47.3±15.5 *

50S
100.0±14.6
31.4±5.5 *
6.0±2.7 *
11.1±3.5 *

Cells were grown in the presence of 5µg/mL paromomycin or azithromycin and 5mM VRC.
Total radioactivity in the 30S or 50S subunit regions of the VRC treated samples was compared
with radioactivity in the same gradient region of control cells. Percentage of the total 30S and
50S subunits in comparison to the control is shown. Results are the means ± standard error of 3
independent experiments. (*) statistically significant with a P value <0.05
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The effect of VRC on subunit synthesis rates was measured by a 3H-uridine pulse and chase
labeling procedure. Figure 3.2 shows that the rates of 30S (Fig. 3.2a) and 50S (Fig. 3.2b) subunit
formation in the absence of VRC. Assembly was complete in 60 min at 27°C (Figure 3.2).
Growth with 5mM VRC lengthened the time for the rate of subunit assembly by about 24-fold,
with 50% of net subunit formation completed in 120 min.

FIG 3.2 Subunit synthesis rates from 3H uridine pulse-chase labeling assays. (a) Rates of
formation of 30S subunits in cells growing with or without 5mM VRC. (b) Rates of formation of
50S subunits in cells growing with or without 5mM VRC. Results are the means ± standard error
of 2 independent experiments.

Antibiotics which inhibit ribosomal subunit formation also affect translation (33). Protein
synthesis rates in bacterial cells were measured in the presence of several concentrations of VRC
to examine its effect on translation. The data in Figure 3.3 demonstrate that the rate of protein
synthesis was increased slightly with increasing VRC concentrations but no inhibitory effects
were seen. Combined with the decrease in 30S and 50S subunits, the protein synthesis results
indicate that VRC affects the assembly of ribosomal subunits without affecting either subunit’s
function and further indicates that VRC inhibits rRNA processing ribonucleases.
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FIG 3.3 Protein synthesis rates for cells growing without and with VRC. Results are the
means ± standard error of 2 independent experiments.

The effect of VRC and the two antibiotics on rRNA turnover was examined in more detail.
The Agilent chip methodology was used to examine rRNA status in all cells. Figure 3.4 shows
the gel pattern and Table 3.4 gives a quantitative analysis of the rRNA distribution. The amounts
of both 16S and 23S rRNAs in E. coli were reduced by each experimental treatment compared to
those in untreated control samples (Table 3.4). The treatment of antibiotics alone increased
rRNA while decreasing 16S and 23S rRNA. VRC alone reduced the 16S and 23S rRNA
amounts, and increased the RNA degradation observed when either antibiotic was added. Bands
the approximate size of the precursor forms of 16S rRNA were apparent in each case where
antibiotics were added and appeared to show more accumulation when VRC and antibiotics were
present. The band representing the 16S precursor can be seen directly above the 16S rRNA band
in the Agilent gel (Table 3.4).
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b

a

FIG 3.4 Agilent gel analysis of total RNA. RNA samples were analyzed by the Agilent
Bioanalyzer. (a) RNA isolated from cells grown in the presence of 5µg/mL antibiotics. Lane 1,
control cells; lane 2, cells grown with paromomycin; lane 3, cells grown with azithromycin;
lane 4, cells grown with 5mM VRC; lane 5, cells grown with paromomycin and 5mM VRC; lane
6, cells grown with azithromycin and 5mM VRC. (b) RNA isolated from cells grown in the
presence of 10µg/mL antibiotics. Lanes are as in (a)

TABLE 3.4 The amount and distribution of 23S, 16S, and small RNA species as determined by
Agilent gel electrophoresis analysis
Treatment
Control
Paromomycin
Azithromycin
Control + VRC
Paromomycin + VRC
Azithromycin + VRC

RIN
9.2±0.7
6.5±0.1 (71.2)
6.1±0.1 (65.8) *
9.6 ±0.5 (104.3)
5.7±0.1 (62.0) *
5.6±0.1 (60.9) *

% Total area
Small RNA
16S rRNA
22.63±13.1
31.47±4.5
23.30±2.3 (103.0)
15.35±0.2 (48.8)
27.25±3.7 (120.4)
15.10±0.1 (48.0)
13.53±3.0 (59.8)
24.57±2.6 (78.1)
38.55±0.2 (170.3)
12.00±0.1 (38.1) *
38.90±2.3 (171.9)
8.65±0.2 (27.5) *

23S rRNA
43.73±5.7
13.05±0.2 (29.8) *
7.10±0.1 (16.2) *
35.93±10.1 (82.2)
6.35±0.1 (14.5) *
4.50±0.1 (10.3) *

Cells were grown in the presence of 10µg/mL paromomycin or azithromycin and 5mM VRC.
RNA in each gel region from Figure 3.4 was computed by analysis of the electropherograms
using Agilent software. Percentage of the total RNA in comparison to the control in each gel
region is shown. The RNA integrity number (RIN) is indicated. Results are the means ± standard
error of 2 independent experiments. (*) statistically significant with a P value <0.05
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Northern hybridization analysis was used to examine the rRNA fragmentation with more
specificity. Probes specific for 16S and 23S rRNA sequences were used to test for the
degradation of each type of rRNA. The gel pattern is shown in Figure 3.5, and shows that equal
amounts of RNA were loaded onto the gel. The probe hybridization results are shown in Figure
3.6, and indicate that VRC alone produced some fragmentation of 16S (Figure 3.6a). Each
antibiotic stimulated 16S rRNA fragmentation as shown previously (15). However, when VRC
and the antibiotics were used together, the fragmentation of both rRNA species was enhanced
and there was an increase in the smaller RNA fragments (Fig. 3.6). The addition of VRC in
combination with VRC led to an increase in 23S rRNA fragmentation (Figure 3.6b). These
results confirm the degradation of rRNAs indicated by the gradient centrifugation and Agilent
gel results.

FIG 3.5 Analysis of rRNA fragmentation by gel electrophoresis. RNA samples are: lane 1,
control cells; lane 2, cells grown with 10µg/mL paromomycin; lane 3, cells grown with 10µg/mL
azithromycin; lane 4, cells grown with 5 mM VRC; lane 5, cells grown with 10µg/mL
paromomycin and VRC; lane 6, cells grown with 10µg/mL azithromycin and VRC.
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FIG 3.6 Northern hybridization analysis of rRNA fragmentation. RNA was isolated from cells
grown in the presence of 10µg/mL antibiotics and/or 5mM VRC. (a) 16S rRNA hybridization.
The samples are lane 1, control cells; lane 2, cells grown with paromomycin; lane 3, cells grown
with azithromycin; lane 4, cells grown with 5 mM VRC; lane 5, cells grown with paromomycin
and VRC; lane 6, cells grown with azithromycin and VRC. (b) 23S rRNA hybridization. Lanes
as in (a). Position of estimated sizes of the rRNA fragments are indicated.
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DISCUSSION
Bacterial ribosomes are essential structures in all prokaryotic cells. Expression of genetic
information relies on accurate and rapid translation of mRNA sequences. A very large number
of antimicrobial agents target the translation process causing either bacterial stasis or
bacteriocidal effects (9, 24). Ribosomal subunit formation is an essential process for bacterial
cell growth and viability and is also a target for many of these same translational inhibitors (9).
The present work builds on several of our previous findings regarding various aspects of
antibiotic inhibition of bacterial ribosome formation (6, 8, 13, 15, 25, 26, 34). A large number of
different translational inhibitors can stall ribosomal subunit formation in growing cells (10-12).
Mutant strains of E. coli deficient in specific RNases showed an enhanced sensitivity to both
macrolide (31, 34) and aminoglycoside (16) antibiotics, and subunit formation was impaired in
each case while rRNA degradation was stimulated. In addition, treatment of S. aureus with an
inhibitor of RNases, VRC, promoted similar effects, slowing subunit formation and enhancing
rRNA turnover (17). The present work extends the evidence showing that impairment of subunit
formation by mutation or small molecule inhibitors is detrimental to cell growth. It is
hypothesized that the increase in viable cells when paromomycin and VRC are present is due to
an effect on messenger RNA turnover (21, 27). This is because VRC is efficient at decreasing
ribonucleases and ribonucleases have been shown to be important in mRNA turnover (2, 5). One
surprising observation was increased viability of E. coli cells treated with paromomycin and
VRC (Table 3.1). At this time, we have no explanation for the increase in cell viability in these
cells since they have also been shown to have a significant decrease in subunit assembly and an
increase in 16S and 23S rRNA fragmentation.
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The specific ribonuclease(s) inhibited by VRC in these cells are unknown. RNase III is one
likely target since the formation of both subunits was impaired to the same extent. This enzyme
generates both precursor 16S and 23S rRNAs from the primary transcript (37) and is a
endoribonuclease, the likely substrate for VRC (2). Other processing endo-RNases like RNase E,
G, R or PH could also be affected by VRC (16). VRC may certainly have other effects on tRNA
or mRNA metabolism in cells in addition to the inhibitory effect on subunit formation. These
remain to be investigated.
A separation of the inhibition of subunit formation and subunit function in translation is a
finding from this research. A large reduction in the rate of synthesis of both subunits was
revealed without a concomitant reduction in translation rates. Preexisting ribosomes in VRC
treated cells seem capable of normal rates of protein synthesis. This data further indicates that
VRC is reducing the rate of ribosomal subunit formation without affecting the function of the
bacterial ribosome. Due to the lack of inhibition of translation (Figure 3.3) the effects of VRC
are more than likely due to assembly inhibition and not an effect on translation.
The results described here can be interpreted as follows. Either of the two antibiotics is
capable of binding to a subunit precursor particle and stalling subunit maturation, as we have
previously demonstrated (15, 25). VRC alone likely impairs the processing of rRNA precursor
sequences, a process essential for subunit maturation as well (17). Combining VRC with an
antibiotic will generate a stalled subunit precursor in a cell with a reduced rRNA processing
capability, thus enhancing the effectiveness of the antimicrobial agent.
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Inhibition of rRNA processing RNases indicates a new antimicrobial target in cells. A
search for other small molecule inhibitors of RNase activity or the application of current RNA
interference methods may promote the development of more effective current or novel
antimicrobial therapies.
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ABSTRACT
Objectives: The discovery of new antibiotic targets is important to stem the increase in antibiotic
resistance against most currently used antimicrobials. The bacterial ribosome is a major target
for a large number of antibiotics which inhibit different aspects of translation. Some of these
antimicrobial agents also inhibit ribosomal subunit formation as a second cellular target. Precise
subunit assembly requires the activity of several distinct RNases for proper rRNA processing.
The present work shows that the vanadyl ribonucleoside complex (VRC) inhibited RNases
involved in ribosomal subunit formation without an effect on translation.

Materials and methods: Methicillin sensitive and methicillin resistant strains of Staphylococcus
aureus were examined for the inhibitory effects of VRC on cell viability by colony counting.
Protein synthesis rates were measured by isotopic methionine incorporation. Ribosome synthesis
was measured by isotopic uridine incorporation into ribosomal subunits as displayed on sucrose
gradients. Pulse and chase radiolabeling was used to measure subunit synthesis rates. RNA
turnover was determined by Agilent assay.

Results: The rates and amounts of subunit synthesis were significantly reduced in the presence
of the compound. Ribosomal RNA was degraded and cell viability was reduced as a
consequence. VRC also enhanced the inhibitory effects of macrolide and aminoglycoside
antibiotics on ribosome formation.
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Conclusions: Bacterial ribosomal subunit synthesis was specifically impaired in VRC treated
cells with the rates and amounts of both subunits reduced. Cell viability was significantly
reduced and rRNA turnover was stimulated.
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Introduction
Antibiotics play an important role in global health. However, antibiotic resistance is becoming an
increasing problem world-wide 1. The discovery of novel drug targets and new types of
antimicrobial agents is necessary to control infections caused by resistant microorganisms 2.
A major cellular target for various, currently used antimicrobial agents is the bacterial
ribosome. Many steps in the complex process of translation can be inhibited by different
compounds. Information on the specific inhibitory effects of many translational inhibitors has
been reviewed recently 3. The biogenesis of the large and small ribosomal subunit in bacteria is a
second target for many of these same antibiotics 4.
Bacterial ribosomal subunit assembly begins with specific ribosomal proteins adding to
the nascent 16S, 23S, and 5S ribosomal RNA transcripts. For both 30S and 50S synthesis, an
intermediate precursor particle is formed initially. These particles contain a subset of the total
ribosomal proteins found in the mature subunit and precursor forms of the 16S and 23S rRNA 5.
Endo- and exonucleolytic cleavage of the precursor rRNAs by ribonucleases is essential for
generation of the mature subunits 6. Mutant strains of E. coli deficient in specific RNases are
hypersensitive to azithromycin 7 and to aminoglycoside antibiotics (A. F., unpublished).
Maturation of the precursors into mature subunits is delayed in these mutants and an increase in
the degradation of rRNA can be observed 7. Antibiotics targeting subunit assembly inhibition has
been investigated 8; however, the use of RNase inhibition to potentiate the effects of currently
used antibiotics has not been examined.
The vanadyl ribonucleoside complex (VRC) is a low molecular weight inhibitor of
RNases that has been used during the isolation of RNA from cells 9-11. It is an effective inhibitor
of cellular RNases although its target specificity is unknown. We reasoned that VRC could target
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and inhibit RNases involved in ribosomal subunit assembly and thus function as a novel
antimicrobial agent. This work shows that VRC can specifically inhibit ribosomal subunit
formation in both methicillin sensitive (MSSA) and methicillin resistant (MRSA) S. aureus cells
without an inhibitory effect on protein synthesis. VRC was found to enhance the inhibitory
effects of paromomycin and azithromycin in these organisms. The results indicate that RNases
may be a novel antibiotic target.

Material and Methods
Cellular growth and viability
Methicillin sensitive Staphylococcus aureus RN1786 12 and the methicillin resistant strain A1024
13

were grown at 37oC in tryptic soy broth (TSB). After one hour of initial bacterial growth,

5mM VRC (New England BioLabs) was added to the cells. For some experiments, paromomycin
or azithromycin were added at a concentration of 1.5µg/mL or 5µg/mL respectively. Growth
rates were measured as an increase in cellular density over time using a Klett-Summerson
colorimeter as previously described 14. Cellular viability was determined by colony counting on
TSB agar plates after serial dilution as described 15.
Protein synthesis assay
Cells were grown as described above in the presence or absence of 5mM VRC. After two
cellular doublings, 1µCi/mL of 35S-methionine (1175 Ci/mmol, MP Biomedicals) was added.
Following the addition of the isotope, three 0.2mL samples were removed at 5 minute intervals.
Each sample was precipitated in 10% TCA with 100µg/ml of BSA, collected and washed on
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Whatman GF/A glass fiber filters. The filters were placed into vials containing 3mL Scintisafe
gel. 35S- Methionine radioactivity was measured by liquid scintillation counting.
Uridine pulse and chase labeling
Two 12ml cultures of cells, one control and one with VRC at 5mM were grown to a Klett of 40.
The cells were pulse labeled with 1µCi/ml 3H-uridine (30 Ci/mmol, Am. Radiochemicals) for 90
sec and then chased with uridine at 25µg/ml. At intervals, 2ml samples were removed, collected
by centrifugation, washed and stored frozen before lysis for sucrose gradient centrifugation as
described 7, 16.
Ribosomal subunit assembly
Bacterial cell cultures were grown in TSB as described. Following the addition of VRC at a
Klett of 20, paromomycin or azithromycin was added to the appropriate culture. After 15
minutes of growth with the antibiotics, 3H uridine at a concentration of 1µCi/mL and uridine at a
concentration of 2µg/mL were added. The cells were allowed to grow for two cellular doublings.
At that time, uridine was added to 50µg/mL and the cells were incubated an additional 15
minutes. Cells were collected by centrifugation and stored frozen at -70oC.
Cellular lysates were prepared with lysostaphin, DNase I and Trition X100 as previously
described 16. The samples were centrifuged through 5-20% sucrose gradients in S buffer in an
SW41 rotor at 187813 x g for 3.5 hours 7. Following centrifugation, sample fractions were
collected by pumping them through an ISCO Model UA-5 absorbance monitor set at 254nm. The
fractions were collected into vials and mixed with 3mL Scintisafe gel before measuring the 3H
uridine by liquid scintillation counting.
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Agilent bioanalysis of RNA
Bacterial cells were grown as previously described above. At a density of 4x108 cells/mL, the
cells were collected by centrifugation and RNA was extracted from the cell pellet. Total RNA
was isolated by a spin column procedure with the RNA isolation kit from Norgen (Norgen
Biotek Corp). RNA was examined using an Agilent Bioanalyzer 2100 and the RNA 6000 chip.
Typically 0.5 to 1µg of RNA was analyzed via chip analysis conducted according to the
manufacturer’s instructions for total RNA analysis.
Eukaryotic cell growth
Growth of eukaryotic cells in tissue culture was performed as follows: 20,000 macrophage
(RAW 264.7 cells; 17) or 10,000 fibroblast cells (BJ cells; ATCC) were seeded into a 96-well
plates with 200µL supplemented RPMI 1640 or DMEM media respectively. Both macrophage
and fibroblasts were grown at 37oC in a 5% CO2/95% air humidified atmosphere. After two or
twelve hours of initial growth respectively, 0.5, 1, or 5mM VRC were added to the appropriate
wells. After an additional two hours of growth for each cell type, 10µg/mL of paromomycin or
azithromycin was added to the wells. The cells were allowed to grow for approximately 32
additional hours before performing a Cell Titer 96® AQueous one solution cell proliferation
assay as per manufacturer’s instructions (Promega).
Statistical analysis
Statistical differences were determined by Student t-test. Each antibiotic or VRC sample was
compared to the control cells without VRC or antibiotics. In each table, an asterisk indicates a
statistical significance of P<0.05.
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Results
The VRC was initially tested to see if it had an inhibitory effect on cell growth and viability. In
both methicillin sensitive and methicillin resistant S. aureus cells, the addition of VRC decreased
cell viability (Table 4.1). When 5mM VRC was used, cell numbers were decreased by over 90%
in both strains. The addition of paromomycin alone led to a 92% and 18% reduction in cell
viability for MSSA and MRSA cells respectively, while azithromycin led to a 92% and 95%
decrease. VRC also enhanced the inhibitory effects of paromomycin and azithromycin on cell
viability. The addition of VRC led to an increase in the efficiency of the antibiotics as seen by a
statistically significant decrease in total viable cell counts compared with the effects of the
antibiotics alone (Table 4.1).

Table 4.1. Effect of VRC and antibiotics on cell viability of S. aureus cells
Cell viability (x107/mL)
Methicillin sensitive S. aureus (MSSA)
none
209±66.7
MSSA
paromomycin
17±16.5 (8.1) *
MSSA
azithromycin
16±5.4 (7.7) *
MSSA
VRC
11±5.4 (5.3) *
MSSA
paromomycin + VRC
8±7.8 (3.8) *
MSSA
azithromycin + VRC
2±0.4 (0.96) *
Methicillin resistant S. aureus (MRSA)
none
306±85.9
MRSA
paromomycin
252±15.5 (82.4)
MRSA
azithromycin
17±6.2 (5.5) *
MRSA
VRC
5±1.3 (1.6) *
MRSA
paromomycin + VRC
11±5.9 (3.6) *
MRSA
azithromycin + VRC
1±0.6 (0.32) *

Strain

Inhibitor

The percentage reduction in viability compared with the control cells for each strain is listed in
parenthesis. Results are the means ± standard error of 5 independent experiments. (*) statistically
significant with P<0.05
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Ribonucleases are essential for both ribosomal subunit assembly and for turnover of
mRNA after translation. The inhibitory effect of VRC on translation and subunit formation was
examined separately. The incorporation of 35S-methionine into total cellular proteins was
examined in both strains in the absence and presence of VRC. As Figure 4.1 shows, the addition
of VRC led to a slight increase in protein synthesis rates in both methicillin sensitive (MSSA)
and methicillin resistant (MRSA) S. aureus cells; however, no significant inhibitory effect on the
rate of translation was observed.

(
(

) MSSA without VRC (
) MRSA without VRC (

) MSSA with VRC
) MRSA with VRC

Figure 4.1. Protein synthesis rates for MSSA cells and MRSA cells grown without or with
5mM VRC. Results are the means ± standard error of 3 independent experiments.

Ribosomal subunit assembly was examined in both strains by 3H uridine labeling during
growth in the absence and presence of 5mM VRC. The subunits were separated by sucrose
density gradient centrifugation to show the distribution of 3H uridine into the ribosomal subunits.
90

Figure 4.2a and 4.2b show the sucrose gradient profiles for the labeled subunits. In both
microorganisms there was an overall 90% reduction in the formation of both subunits in the
VRC treated samples when compared with the control. The data showed a 15 to 25% increase in
3

H uridine labeled RNA in the slowly sedimenting top gradient fractions (Figure 4.2; Table 4.2).

This result is indicative of rRNA degradation 7.

Without VRC (

)

With VRC (

)

Figure 4.2. Sucrose gradient profiles of 3H uridine labeled ribosomal subunits isolated from
cells grown without or with 5mM VRC. (a) Gradient profile for MSSA cells. (b) Gradient
profile for MRSA cells. Note the differences in the left (without VRC) and right (with VRC)
axis.

Table 4.2. Distribution of 3H uridine labeled RNA in sucrose gradient regions
% Total gradient radioactivitya

Strain

Top

30S

50S

Methicillin sensitive S. aureus Control

33.17±1.0

21.68±0.1

41.58±0.9

Methicillin sensitive S. aureus + VRC

57.03±1.8
(171.9) *
30.72±1.5

14.65±0.8
(67.6) *
17.47±2.2

24.57±0.8
(59.1) *
47.88±0.7

44.67±1.6
(145.4) *

17.68±0.3
(101.2)

32.98±2.0
(68.9) *

Methicillin resistant S. aureus Control
Methicillin resistant S. aureus + VRC
a

Radioactivity in gradient fractions corresponding to the top, 30S and 50S regions was
calculated as a percent of the total radioactivity in the gradient. Results are the means ±
standard error of 3 independent experiments. (*) statistically significant with a P value <0.05
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The influence of VRC on the rate of ribosomal subunit formation was examined by a 3H
uridine pulse and chase labeling procedure. The rates of subunit formation in the absence of the
inhibitor were equivalent to those observed previously in S. aureus 16, 18 (Figure 4.3). Synthesis
of both subunits was completed by 60 minutes at 27°C. Compared with control cultures, VRC
reduced the rate of formation of both subunits in these organisms. The 50S subunit assembly rate
was lengthened 4-fold under these conditions (Figure 4.3).

With VRC (

)

Without VRC (

)

Figure 4.3. Kinetics of ribosomal subunit formation in cells growing with and without 5mM
VRC. (a) Rates of formation of 30S subunits in MSSA cells. (b) Formation of 50S subunits in
MSSA cells. (c) Rates of formation of 30S subunits in MRSA cells. (d) Formation of 50S
subunits in MRSA cells. Results are the means ± standard error of 2 independent experiments.

The status of rRNA in control and VRC treated cells was examined by the Agilent
Bioanalyzer analysis. Significant decreases in the relative amounts of both16S and 23S rRNA
were observed in VRC treated cells of both strains (Figure 4.4). Bands representing the
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approximate size of the precursor forms of both rRNA species could be seen directly above the
16S and 23S rRNA bands. Growth with both VRC and antibiotics led to an increase in
fragmented rRNA in these cells (Table 4.3). In both strains, the addition of VRC alone led to a
significant 2 to 3- fold increase in smaller RNA molecules. The addition of VRC and
paromomycin or azithromycin also led to a significant increase in small RNA molecules in
MRSA cells (Table 4.3).

(a) MSSA

(b) MRSA

Figure 4.4. RNA samples analyzed by the Agilent Bioanalyzer. Total RNA was isolated from
MSSA and MRSA cells grown without and with VRC and antibiotics. (a) Agilent chip analysis
of RNA from MSSA cells. The RNA samples are: lane 1, control cells; lane 2, cells grown with
paromomycin; lane 3, cells grown with azithromycin; lane 4, cells grown with 5mM VRC; lane
5, cells grown with paromomycin and 5mM VRC; lane 6, cells grown with azithromycin and
5mM VRC. (b) Agilent chip analysis of RNA from MRSA cells. Sample lanes are the same as
in (a).
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Table 4.3. Distribution of small RNA species after Agilent gel separation
Strain
Methicillin sensitive S. aureus (MSSA)
MSSA
MSSA
MSSA
MSSA
MSSA
Methicillin resistant S. aureus (MRSA)
MRSA
MRSA
MRSA
MRSA
MRSA

Inhibitor
none
paromomycin
azithromycin
VRC
paromomycin + VRC
azithromycin + VRC
None
paromomycin
azithromycin
VRC
paromomycin + VRC
azithromycin + VRC

% Total areaa
15.60±0.6
28.90±0.005 (185.3) *
41.10±3.2 (263.5) *
19.20±1.0 (123.1)
19.70±0.2 (126.3) *
26.70±0.8 (171.2) *
8.80±0.4
14.35±0.5 (163.1)
25.05±2.0 (284.7) *
14.80±0.4 (168.2) *
11.80±1.0 (134.1)
31.10±0.1 (353.4) *

a

Total RNA in gel bands smaller than 16S rRNA was computed by analysis of the
electropherograms using Agilent software. Results are the means ± standard error of 2
independent experiments. (*) statistically significant with a P value <0.05

In order to determine if VRC could be used as an antimicrobial agent in eukaryotic cells,
the compound and antibiotics were applied to fibroblasts and to macrophage cells in culture.
When antibiotics were added to the eukaryotic cells, there was no significant change in overall
cellular viability. However, when 1mM or 5mM VRC was added to the eukaryotic cell cultures,
there was a 90% and 98% reduction in cell viability. This led to the conclusion that VRC could
not be used to enhance antibiotic effectiveness in eukaryotic cells.

Discussion
The bacterial ribosome is an important target for current antibiotic treatments 3. These
antimicrobial agents target both translation and ribosomal subunit formation 4. For ribosomal
subunit biogenesis, a number of different endo-and exoribonucleases are required. These include
RNases III, E, G, T and PH 6. This processed RNA is used to form the subunit precursors and
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without an inhibitor present, the precursors mature to generate the 30S and 50S ribosomal
subunits respectively 5.
As previously stated, other endo- and exoribonucleases are required to complete the
processing of 16S, 23S, and 5S rRNA. This processed RNA is used to form the 21S and 32S
subunit precursors and without an inhibitor present, the precursors mature to form the 30S and
50S ribosomal subunits respectively 5. When an inhibitor, such as an antibiotic, is present the
precursor RNA is broken down. Ribonucleases are used by the cell to degrade the subunit
precursors and their rRNA into nucleotides to be recycled 4, 5, 19. RNase activity is therefore an
important mechanism for both mRNA turnover and rRNA processing.
Our previous research has shown that E. coli strains deficient in RNase E, RNase II or
polynucleotide phosphorylase (PNPase) were hypersensitive to azithromycin 7. These mutants
showed an enhanced accumulation of 23S rRNA, a stimulation of rRNA breakdown and a
reduced recovery rate of 50S ribosomal synthesis after azithromycin removal. These results
suggested that the use of an RNase inhibitor in bacterial cells could enhance the efficiency of
current antibiotics. These mutant strains are increased in sensitivity to the aminoglycoside
antibiotics, neomycin and paromomycin, while 16S rRNA turnover is stimulated in some of
these mutant strains as well (A. F., unpublished).
The present results can be interpreted to suggest that the antibiotics alone stall subunit
formation with precursor particle accumulation 20, 21. VRC alone inhibits the activity of critical
rRNA processing RNases. Either antibiotic with VRC causes the accumulation of a subunit
precursor and the inhibition of rRNA processing, leading to an enhanced inhibitory effect on
subunit formation and a further reduction in cell viability. The relatively high concentration of
VRC used here (5mM) and its inhibitory effects on eukaryotic cells would preclude its use as a
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human antimicrobial agent. Its effects on ribosome synthesis indicate its use as a model
compound and suggest that inhibition of bacterial RNases can be a novel target for drug
development.
It is important to note that VRC specifically inhibited subunit formation without an effect on
translation. This reinforces the established idea that translation and subunit assembly are separate
and equivalent targets for ribosomal antibiotics 4, 22-24. Either process can be a targeted by
specific antimicrobials. The cellular RNase target for VRC is unknown but RNase III is a likely
target since the formation of both subunits was affected to the same extent. Inhibition of subunit
assembly-specific RNases by VRC suggests that these RNases may be a target by other small
molecule inhibitors or by RNA interference approaches. This research further indicates the
importance of RNases as a novel target in antibiotic research.
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CHAPTER 5
SUMMARY

Antibiotics play an important role in society and global health. As the use and misuse of
antibiotics increases, so does the prevalence of bacterial antibiotic resistance (Hawkey and Jones
2009; Rosen 2011; Tenover 2001). Due to this increasing problem, the development of novel
antibiotic targets is a constant research endeavor.
Many commonly used antibiotics function by targeting the bacterial ribosome.
Aminoglycosides have been shown to bind to the 30S ribosomal subunit to inhibit the recycling
of the ribosomal subunit and affect the translational accuracy (Foster and Champney 2008;
Mehta and Champney 2002; Sutcliffe 2005). Additionally, aminoglycoside research has
demonstrated that these antibiotics also target the 50S ribosomal subunit (Borovinskaya and
others 2007; Campuzano and others 1979; Scheunemann and others 2010). Macrolides
specifically target the 50S ribosomal subunit but not the 30S subunit in the bacterial cell
(Champney 2008; Champney and Burdine 1998b; Champney and Rodgers 2007; Chittum and
Champney 1995; Silvers and Champney 2005; Usary and Champney 2001).
The bacterial ribosome is composed of a small (30S) and large (50S) subunit. Each of these
subunits are made up of ribosomal RNA and various proteins. The 30S subunit is composed of
16S rRNA while the 50S subunit is composed of 23S and 5S rRNA (Champney 2003). In order
for the proper formation of the subunits to occur, the ribosomal RNA must be processed from a
primary RNA transcript into mature RNA. RNases are the enzymes involved in this process.
Ribonucleases such as RNase III, E, G, and PH all play pivotal roles in rRNA processing as seen
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in Figure 1.7 and Table 1.2 (Davies and others 2010; Gutgsell and Jain 2012; Kaczanowska and
Rydén-Aulin 2007; Song and others 2011).
Along with rRNA processing, RNases also play important roles in rRNA degradation and
turnover. Figure 1.6 illustrates the importance of RNases in rRNA degradation. When an
inhibitor (such as an antibiotic) is introduced into a bacterial cell during ribosome formation,
RNases play key roles in the breakdown of the 30S and 50S subunits. Once degraded, the rRNA
can then be recycled back into the bacterial ribosome assembly process without the attached
translational inhibitors (Champney 2006). RNases II, R, E, and PNPase are all involved in the
degradation of rRNA as shown in Table 1.2 (Arraiano and others 2010; Cheng and Deutscher
2002; 2003; Vanzo and others 1998).
Prior RNase research by Silvers and Champney demonstrated that when E. coli cells were
deficient for RNase E, RNase II, or PNPase, these cells displayed an increased sensitivity to the
macrolide antibiotic, azithromycin (Silvers and Champney 2005). Additionally, these cells had
an accumulation of the 32S precursor for the 50S ribosomal subunit and a reduced recovery rate
of the 50S subunit once the antibiotics were removed. This particular work illustrated the
importance of ribonucleases in 23S rRNA turnover and antibiotic sensitivity to azithromycin
(Silvers and Champney 2005). This work also indicated that RNases might serve as a potential
antibiotic target.
A study was conducted to first determine if the absence of RNases in E. coli cells would
show an increased sensitivity to aminoglycosides (Chapter 2) as was seen for Silvers and
Champney to a macrolide (Silvers and Champney 2005). The results showed that E. coli cells
deficient for RNase III, E, R, G, or PH displayed a significant decrease in cell viability in the
presence of neomycin or paromomycin. Additionally, RNase PH deficient cells demonstrated a
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significant reduction in 30S and 50S ribosomal subunits and a significant reduction in 16S and
23S rRNA. RNase III is an essential enzyme in the cleavage of the primary RNA transcript
(Deutscher 2009). RNases E and G are found to function in the processing of 16S rRNA (Li and
others 1999). RNase G, along with RNase PH, is involved in maturation of 23S rRNA (Gutgsell
and Jain 2012; Song and others 2011). In addition to rRNA maturation, RNase is involved in
rRNA degradation by forming part of the bacterial degradosome (Deutscher 2009; Vanzo and
others 1998).
The data from Chapter 2 and Silvers and Champney (Silvers and Champney 2005) indicated
that the loss of certain RNases led to an increased susceptibility to currently used antibiotics.
This finding is an important point because antibiotic resistance to aminoglycosides and
macrolides is documented (Anderson 1999; Cars and others 2011; Högberg and others 2010;
Zinner 2005). Novel antibiotic targets, such as ribonucleases, could hold an important key to the
development of new drugs and the improvement of current ones.
Due to the fact that RNase mutants are not found in nature, the second aim of this study was
to determine if the use of an RNase inhibitor would act to inhibit RNases important to RNA
maturation and thereby potentiate the effects of an aminoglycoside and a macrolide (Chapter 3).
Vanadyl Ribonucleoside Complex (VRC) is a low weight molecular inhibitor of RNases that is
mainly used during RNA isolations (Berger 1987; Berger and others 1980). While it is unknown
which specific RNases are inhibited by VRC, it has been proposed that VRC specifically targets
endoribonucleases (Berger 1987). The work showed that VRC led in a slight decrease in viable
cell counts and had an additive effect on E. coli when azithromycin was also added.
Paromomycin and VRC led to an increase in viable cells that, while not completely understood,
could possibly be attributed to a decrease in mRNA turnover. Additionally, the presence of VRC
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was shown to decrease ribosomal subunit assembly and increase the fragmentation of 16S and
23S rRNA, especially when azithromycin was also present. This work showed that an inhibitor
of RNases could be used in gram negative E. coli cells to potentiate the effects of the macrolide,
VRC. VRC did not appear to increase the overall effectiveness of the aminoglycoside,
paromomycin. The exact mechanism for why paromomycin and VRC led to an increase in E.
coli cell viability is not known. The addition of VRC and azithromycin led to a decrease, and the
addition of VRC and paromomycin or azithromycin led to a significant decrease in cell viability
for both MSSA and MRSA cells. It is postulated that the reason for the increase in E. coli cells
incubated paromomycin and VRC is due to the differences in bacterial cell walls in gram
negative and gram positive bacteria and the different targets of aminoglycoside verses macrolide
antibiotics.
In addition to use of VRC in E. coli, it was hypothesized that VRC would act similarly in
different bacteria. Methicillin resistant strains of Staphylococcus aureus began as hospital
acquired infections but as antibiotic resistance spread, the introduction of community acquired S.
aureus began to appear (Hawkey and Jones 2009; Zinner 2007). The final aim of this research
was to determine if VRC would potentiate the effects of an aminoglycoside and a macrolide in a
gram positive bacterial species (Chapter 4).
Methicillin sensitive and methicillin resistant Staphylococcus aureus were incubated with
VRC and paromomycin (an aminoglycoside) or azithromycin (a macrolide). The study
demonstrated that VRC alone reduced the viable cell counts in both types of S. aureus. The
addition of VRC also led to a reduction in the assembly of the 30S and 50S assembly in S.
aureus cells. The results also showed that when either of the antibiotics was added, the effects of
the antibiotics were potentiated by the VRC. This study further demonstrated that an inhibitor of
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bacterial RNases is effective in not only gram negative bacteria, as seen in Chapter 3, but also
potentially dangerous gram positive bacteria (i.e. methicillin resistant S. aureus). A summary of
all three aims is seen in Table 5.1. The table shows that E. coli lacking specific RNases
demonstrated an increased sensitivity to aminoglycosides and that the use of VRC led to an
increase in the inhibitory effects of an aminoglycoside and a macrolide.
Together, this study demonstrates a novel antibiotic drug target in the bacterial
ribonucleases. It also shows a new use for an RNase inhibitor to potentiate the effects of current
antibiotics in both a gram negative, an antibiotic sensitive gram positive, and an antibiotic
resistant gram positive bacterial species. While VRC was shown to have cytotoxic effects on
eukaryotic cells (Chapter 4), future studies to identify different prokaryotic-selective RNase
inhibitors could be useful to antibiotic research. It would be interesting to determine if antibiotic
resistant bacterial strains up-regulate specific RNases to increase the rRNA turnover in addition
to other methods of resistance. Other future areas of research could involve different RNase
inhibitors to determine if different combinations will increase or decrease antibiotic
susceptibility. With bacterial resistance to current antibiotics on the rise, it is essential that we
research innovative antibiotic targets in order to improve global health and safety.
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Table 5.1: Final dissertation summary
Strain

RNase
Mutation

SK901

None

D10-1

I

SK7622

III

SK5665

E

SK4803

II

N7060

I, II, PNPase

- MG1655 I R

Inhibit 30S
Assembly

Inhibit 50S
Assembly

+

+

+

+

+

I, R

+

+

GW11

G

+

SK6639

PNPase

SK5729

Macrolide
Sensitivity

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

Methicillin Resistant
Staphylococcus aureus + VRC

Increased 23S rRNA
Fragmentation

+

Methicillin Sensitive
Staphylococcus aureus + VRC

Increased 16S rRNA
Fragmentation

I, II,
PNPase, PH

Escherichia coli + VRC

Aminoglycoside
Sensitivity
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